

# **EXHIBIT 23**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY**


**IN RE: JOHNSON & JOHNSON TALCUM  
POWDER PRODUCTS MARKETING, SALES  
PRACTICES AND PRODUCTS LIABILITY  
LITIGATION**

**MDL NO. 16-2738 (FLW) (LHG)**

***THIS DOCUMENT RELATES TO ALL CASES***

**EXPERT REPORT OF KEVIN HOLCOMB, MD, FACOG  
FOR GENERAL CAUSATION *DAUBERT* HEARING**

Date: February 25, 2019

  
Kevin Holcomb, MD, FACOG

## **Personal Background**

Gynecologic oncologists are specialists in the treatment of women with gynecologic malignancies, including cancers of the ovary, uterus, cervix and other sites. It is the only area of oncology wherein one clinician is responsible for both the medical and surgical aspects of a patient's care, and this leads to a unique comprehensive model of cancer therapy. A gynecologic oncologist doesn't just comprehensively treat the cancer of the presenting patient but is also responsible for the identification of additional cancer risks for the patient and her family.

It was this uniqueness that I was immediately drawn to as a 4th year medical student at New York Medical College. Upon graduation, I continued my training as an intern and resident in Obstetrics and Gynecology at The New York Hospital-Cornell Medical Center. Following this four-year experience, I attended a three-year fellowship training in Gynecologic Oncology at Downstate Medical Center/Kings County Hospital. This fellowship, approved by the American Board of Obstetrics and Gynecology ("ABOG"), focused on the study of the causes and treatments for all gynecologic malignancies. My fellowship training occurred in a safety-net hospital in Brooklyn, New York that cares largely for an African American and Afro-Caribbean patient population. This is a demographic with a significantly higher rate of genital talc use and yet a lower risk of ovarian cancer compared with Caucasian women. I was never taught that talc use is an accepted risk factor for gynecologic cancer, to routinely investigate its usage while obtaining a medical history, or to recommend against its use.

After completing my fellowship, I remained on the academic faculty at Downstate as an Assistant Professor until moving to Beth Israel Medical Center in Manhattan to become the Director of Gynecologic Oncology at that institution. I remained there for five years before returning to Weill-Cornell Medicine/New York-Presbyterian Hospital in 2006 as a member of the Gynecologic Oncology division and an Associate Professor at Weill Cornell Medical College. Since that time, I have been promoted to the positions of Director of Gynecologic Oncology, Vice-Chairman of Gynecology, and Director of Minimally Invasive Surgery in the Department of Obstetrics and Gynecology. From April to October of 2018, I was asked by the Dean of the Medical College to serve as the acting Chairman of the department during a nationwide search.

I presently direct a division of four gynecologic oncologists, three physician assistants, and the administrative and research support staff. Despite significant administrative and academic responsibilities, the majority of my time is spent in clinical practice. I have been fortunate to build a busy gynecologic oncology practice and have been named as a "Top Doctor in the New York Metropolitan Area" by Castle-Connolly Inc. since 2009. I have performed approximately 200-225 surgeries per year since the early 2000s and treat approximately 20 new ovarian cancer patients per year. In addition, I am responsible for the follow-up care and treatment of approximately 50 existing ovarian cancer patients per year. This includes managing the chemotherapy, immunotherapy, and targeted therapy of high-risk patients.

As previously mentioned, my clinical responsibilities also include assessing cancer risk in my patients and their families. This includes the identification of genetic, reproductive and environmental risk factors. While I routinely counsel patients about the impact of known cancer

risk factors like cigarette smoking, Human Papilloma Virus (HPV) infection, and family cancer history, I do not inquire (and have never inquired) about prior talc use; nor do I recommend against it for my ovarian cancer patients. I know of no one in my division or specialty who does so, and this is in keeping with the recommendations of the professional societies including the American College of Obstetricians and Gynecologists (“ACOG”) and the Society of Gynecologic Oncology (“SGO”) that offer practice guidelines for the specialty.

In 2010, we were approved by ABOG, in conjunction with our colleagues at Columbia Medical Center, to start a three-year gynecologic oncology fellowship training program. The clinical training and mentorship of ob/gyn residents and gynecologic oncology fellows is an aspect of my career that I find particularly satisfying. I have received numerous teaching awards throughout my career and was recognized by the Council on Residency Education in Obstetrics and Gynecology with the National Faculty Teaching Award in 2002 and 2004. We have graduated eight solid gynecologic oncologists since our inception, and none has been trained to routinely inquire about or recommend against genital talc usage.

As Director of Gynecologic Oncology, I am also responsible for helping to direct the research priorities of the division. We perform clinical, translational, and basic science studies within the department, and I have personally authored or co-authored more than 70 articles in the peer-reviewed literature. My current research interests include population-based outcomes analysis, evaluation of novel biomarkers in ovarian cancer, and translational research on the immunobiology of the ovarian cancer tumor microenvironment. I am the principal investigator for two multi-institutional prospective trials examining the role of the novel serum biomarker, HE4, in the early detection of ovarian cancer, and I recently published on autophagy inhibition as a novel vaginal biomarker for ovarian cancer detection. My division collaborates with scientists within the medical college, and we were involved in the research recently published in *Cell*<sup>1</sup> and *Nature*<sup>2</sup> that were the first to identify the endoplasmic reticulum stress response as an important cause of immunosuppression in the ovarian cancer tumor micro-environment. The ultimate goal of these studies is to identify effective tests for the early detection of ovarian cancer and its precursors as well as therapeutic targets for more effective therapy. In addition to my personal involvement with translational and clinical research, I also act as a reviewer of research submitted for publication to journals such as *Gynecologic Oncology*, *Journal of the American Medical Association*, and *Obstetrics and Gynecology*. In this role, I make recommendations regarding the appropriateness, originality, and validity of the submitted research based on assessment of the study design, statistical analysis and presentation of the findings.

I have always considered advocacy for my patients to extend beyond my role as a clinician. I served as a member of the Harlem Cancer Control Coalition and was a past president of the Board of Advisors for the American Cancer Society Harlem Office. Both of these organizations are dedicated to the eradication of health care disparities, particularly those impacting communities of color. I presently sit on the Scientific Advisory Board of “TEAL,” an ovarian

---

<sup>1</sup> Cubillos-Ruiz JR, *et al.* Tumorigenic and immunosuppressive effects on endoplasmic reticulum stress in cancer. *Cell* 2017; 168: 692-706.

<sup>2</sup> Song M, *et al.* IRE1 $\alpha$ -XBP1 Controls T cell function in ovarian cancer by regulating mitochondrial activity. *Nature* 2018; 562: 423-428.

cancer advocacy organization based in Brooklyn, NY. Since 2009, TEAL has provided over 3 million dollars in research support to some of the most innovative researchers in the nation. I was humbled to be an honoree at the organization's "10 Years of Amazing" Gala in April 2018 at the Brooklyn Museum of Art.

Because of my extensive clinical experience in the treatment of ovarian cancer, my experience as a researcher in the area of gynecologic oncology, my role in the medical education of future gynecologic oncologists, and my role in ovarian cancer patient advocacy, I feel particularly qualified to offer my opinion that there is insufficient data to conclude that genital talc use increases the risk of ovarian, fallopian tube, or primary peritoneal cancer. Together, these cancers account for the majority of gynecologic oncology mortalities in the United States annually and there is no effective screen for any of them. After years of study on the relationship between genital talc and ovarian cancer, and in contrast to the case of cervical cancer and HPV infection, there is no public health program dedicated to the eradication of genital talc use. Much of the debate on the role of genital talc use in the carcinogenesis of ovarian cancer remains in the realm of product liability. In presenting the clinical and scientific data that support my professional opinion, I hope to explain why this is the case.

### **Scope of Report**

I was asked to review the opinions of plaintiffs' three gynecologic oncology experts and to render an opinion as to whether their opinions are supported by the scientific literature and what is known in the scientific community about talc and about the origins of ovarian cancer. My opinions in this report are based on my education, my experience as a gynecologic oncologist and my review of the peer-reviewed published scientific literature. I hold all the opinions in this report to a reasonable degree of medical certainty. I am being compensated at the rate of \$850 per hour for the time I have spent to provide expert opinion in this litigation.

### **Summary of Opinions**

A number of factors may increase the risk for developing epithelial ovarian cancer, including genetic predisposition and reproductive history, and certain environmental exposures. Women who have family members with a history of ovarian cancer are the most susceptible to developing the disease themselves. Other known risk factors, which may vary by histological subtype, include, among other things, nulliparity, infertility, use of hormone replacement therapy drugs and cigarette smoking. Plaintiffs proffer the opinions of a few physicians who claim that genital talc use can also cause ovarian cancer. The scientific literature – and in particular prospective cohort studies, which are the best studies we have to evaluate potential human carcinogens – simply does not support that position. Rather, the best available science indicates that genital talc use is not associated with, much less does it cause, an increased risk of ovarian cancer. In addition, plaintiffs' experts' hypotheses regarding biologic plausibility ignore a host of contradictory studies.

## **Ovarian Cancer Background**

Ovarian cancer has earned its reputation as the most feared gynecologic malignancy by patients and physicians alike. While it is a relatively rare disease with a cumulative lifetime risk of approximately 1.3%, it accounts for more cancer deaths in the United States every year than the remaining gynecologic malignancies combined. In 2018, 22,240 American women were diagnosed with ovarian cancer, and 14,070 are estimated to have died from it.<sup>3</sup> Due to the diversity of cell types that comprise the ovary and the pluripotent nature of the germ cells themselves, the ovary has the potential to develop a large number of distinct histologic types of cancer. Historically, ovarian cancers have been divided into three histologic types based on the cell of origin: epithelial, sex cord-stromal, and germ cell cancers. Each type of ovarian cancer has a unique average age at diagnosis, risk of metastatic disease and mortality, and treatment algorithm. Epithelial ovarian cancer is, by far, the most common cell type and accounts for more than 90% of ovarian cancers.<sup>4</sup> Unfortunately, it is also the cell type with the highest chance of extra-ovarian metastases at the time of diagnosis. Approximately 75% of patients with epithelial ovarian cancer (“EOC”) present with disease that has already spread to the upper abdomen and beyond.<sup>5</sup> This combination of advanced stage of disease at presentation and a natural history of increasing chemotherapy resistance explain the poor survival associated with EOC. When diagnosed at an early stage (I or II), patients can expect 80-90% survival. However, the overall survival at five years is a disappointing 30-40% for the majority of patients who present with advanced stage (III or IV) EOC. Epidemiological studies examining the relationship between talcum powder exposure and ovarian cancer have largely been limited to EOC, and I will restrict the remainder of my report to this specific type.

## **Epithelial Ovarian Cancer**

EOC includes cancers of serous, mucinous, clear cell and endometrioid varieties. Historically, these cell types were commonly combined in clinical and pathologic studies of EOC; however, recent advances in genomics have led to an appreciation of the biological diversity among the various types. It is now well-accepted that the various types of EOC are associated with distinct genetic aberrations, clinical presentations, and even risk factors. For example, nearly all high-grade serous adenocarcinomas of the ovary harbor a mutation in a tumor suppressor gene TP53.<sup>6</sup> In contrast, mucinous adenocarcinoma of the ovary rarely carry this mutation but 40-50% harbor a mutation in KRAS and approximately 19% carry a Her2 Neu mutation.<sup>7</sup> Clear cell and endometrioid adenocarcinomas of the ovary are now known to commonly arise from endometriosis (a common benign gynecologic disorder in reproductive-age women). Even within

---

<sup>3</sup> National Institute of Health, SEER Cancer Stat Facts: Ovarian Cancer. National Cancer Institute. Bethesda, MD, <https://seer.cancer.gov/statfacts/html/ovary.html> (last visited January 2019).

<sup>4</sup> Torre, L *et al.* Ovarian cancer statistics. *CA Cancer J Clin* 2018; 68(4): 284-296.

<sup>5</sup> Sethna, K Bhatt, A. Cytoreductive Surgery and Intraperitoneal Chemotherapy for Advanced Epithelial Ovarian Cancer. Chapter 10 in *Management of Peritoneal Metastases-Cytoreductive Surgery, HIPEC and Beyond*. 2018 pg. 10.

<sup>6</sup> Mullany, LK, *et al.* Wild-type tumor repressor protein 53 (TRP53) promotes ovarian cancer cell survival. *Endocrinology* 2012; 153(4): 1638-1648.

<sup>7</sup> Perren, TJ. Mucinous epithelial ovarian carcinoma. *Annals of Oncol* 2016; 27: i53-i57.

the endometrioid variety, there are two biologically distinct tumor types: low-grade and high-grade. The majority of low-grade endometrioid carcinomas cases harbor  $\beta$ -catenin and KRAS mutations that are usually absent in high-grade tumors.<sup>8,9</sup> The biologic diversity of EOC is not limited to genetic alterations but can also be seen in the risk factors for the various histologic types. For example, cigarette smoking only increases the risk of mucinous carcinoma of the ovary but not the other histologic types.<sup>10</sup> The new appreciation for the complexity surrounding the genetic underpinnings and environmental risks for the various forms of EOC renders the theory that a single environmental exposure, such as talcum powder, could increase the risk for all types of EOC much more difficult to justify scientifically. Not surprisingly, the poorer quality studies suggesting a connection between talc exposure and EOC come to various, and often conflicting, conclusions regarding the association of talc and the various histologic types. The largest association with genital talc use was found with serous adenocarcinoma by Cook *et al.* (1997),<sup>11</sup> Chang and Risch (1997),<sup>12</sup> Cramer, *et al.* (1999),<sup>13</sup> and Gertig *et al.* (2000).<sup>14</sup> In contrast, Harlow, *et al.* (1992)<sup>15</sup> identified the largest association with endometrioid tumors, while Mills, *et al.* (2004)<sup>16</sup> identified mucinous tumors as having the largest association.

### **Ovarian Cancer Risk Factors**

The risk factors for the development of EOC can be divided into genetic predispositions, reproductive factors and environmental factors. There is a strong familial component to the disease. A woman with two first-degree family members with a history of ovarian cancer has a 7% lifetime risk, increased from the baseline risk of approximately 1.3%.<sup>17</sup> The highest risks are seen among women who carry germ-line mutations in ovarian cancer predisposition genes. Mutations in the BRCA1 and/or BRCA 2 tumor suppressor genes are causes of two of the most common ovarian cancer familial syndromes and are associated with lifetime risks of ovarian cancer as high as 44% and 17%, respectively.<sup>18</sup> While the risk of EOC in these patients is

---

<sup>8</sup> Soyama H, *et al.* Pathological study using 2014 who criteria reveals poor prognosis of grade 3 ovarian endometrioid carcinomas, *In Vivo* 2018; 32: 597-602.

<sup>9</sup> Lim D, *et al.* Morphological and immunohistochemical reevaluation of tumors initially diagnosed as ovarian endometrioid carcinoma with emphasis on high-grade tumors. *Am J Surg Pathol* 2016; 40: 302-312.

<sup>10</sup> Soegaard M, *et al.*, Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. *Cancer Epidemiol Biomarkers Prev* 2007; 16: 1160-1166.

<sup>11</sup> Cook LS, *et al.* Perineal powder exposure and the risk of ovarian cancer. *Am J Epidemiol* 1997; 145(5): 459-465.

<sup>12</sup> Chang S and HA Risch. Perineal talc exposure and risk of ovarian carcinoma. *Cancer* 1997; 79: 2396-2401.

<sup>13</sup> Cramer DW, *et al.* Genital talc exposure and risk of ovarian cancer. *Int J Cancer* 1999; 81: 351-356.

<sup>14</sup> Gertig DM, Hunter DJ, Cramer DW, *et al.* Prospective study of talc use and ovarian cancer. *J Natl Cancer Inst* 2000; 92: 249-252.

<sup>15</sup> Harlow BL, *et al.* Perineal exposure to talc and ovarian cancer risk. *Obstet Gynecol* 1992; 80: 19-26.

<sup>16</sup> Mills PK, *et al.* Perineal talc exposure and epithelial ovarian cancer risk in the central valley of California. *Int J Cancer* 2004; 112: 458-464.

<sup>17</sup> Toss A, *et al.*, Hereditary ovarian cancer: not only BRCA 1 and 2 genes. *Biomed Res Int* 2015: 341723.

<sup>18</sup> Kuchenbaecker KB, *et al.* Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *JAMA* 2017; 317(23): 2402-2416.

significantly increased, BRCA 1 and 2 mutations account for only approximately 15% of EOC cases.<sup>19</sup> Less common hereditary ovarian cancer syndromes are associated with mutations in DNA mismatch repair genes (Lynch Syndrome), P53 mutation (Li-Fraumeni Syndrome), and multiple other genes involved in the double-strand DNA breaks repair system, such as CHEK2, RAD51, BRIP1, and PALB2.<sup>20</sup> The number of genes potentially associated with an increased risk of ovarian cancer is continually expanding. It should be noted that even the hereditary syndromes are associated with distinct histologic types of EOC. BRCA 1 or 2 mutation-associated ovarian cancers are most often high-grade serous carcinomas, while Lynch Syndrome is most often associated with endometrioid adenocarcinoma.<sup>21</sup>

Reproductive factors associated with an increased risk of EOC are early menarche (first menses) and late menopause, nulliparity (never haven given birth), infertility, endometriosis, and the use of hormone replacement therapy. Having children, breast feeding and long-term use of oral contraceptives all decrease the risk of EOC.<sup>22</sup> The association of these observations with ovulation led to a theory that “incessant ovulation” increases the risk of ovarian cancer and factors that inhibit ovulation protect against the disease.

One environmental factor that has been associated with an increased risk of EOC is cigarette smoking (mucinous adenocarcinoma).<sup>23</sup> While plaintiffs’ experts have also identified asbestos as a cause of ovarian cancer, it is important to note the conditions under which occupational asbestos exposure has been linked to ovarian cancer.<sup>24</sup> These scenarios include women in the United Kingdom involved in the production of asbestos-containing gas masks during and before World War II (Acheson *et al.*),<sup>25</sup> former employees of a now closed asbestos cement factory in Casale Monferrato, Italy (Magnani *et al.*),<sup>26</sup> and Italian women working in the asbestos-textile industry (Germani *et al.*).<sup>27</sup> Notably, at the time of several of these studies, pathological methods to accurately distinguish between ovarian cancer and peritoneal mesothelioma had not yet been developed. And even if it were true that talc products contain asbestos, there is no evidence to

---

<sup>19</sup> Torre, L *et al.* Ovarian cancer statistics. *CA Cancer J Clin* 2018; 68(4): 284-296.

<sup>20</sup> Toss A, *et al.*, Hereditary ovarian cancer: not only BRCA 1 and 2 genes. *Biomed Res Int* 2015: 341723.

<sup>21</sup> Toss A, *et al.*, Hereditary ovarian cancer: not only BRCA 1 and 2 genes. *Biomed Res Int* 2015: 341723.

<sup>22</sup> Garg PP, *et al.* Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. *Obstet Gynecol* 1998; 92(3): 472-479; Lacey JV Jr, Mink PJ, Lubin JH, *et al.* Menopausal hormone replacement therapy and risk of ovarian cancer. *JAMA* 2002; 288(3): 334-341; Mills PK, *et al.* Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. *Cancer Detect Prev* 2005; 29(2): 124-132.

<sup>23</sup> Faber M, *et al.* Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. *Cancer Causes Control* 2013; 24(5): 1-26.

<sup>24</sup> IARC Monograph. Arsenic, Metals, Fibres, and Dusts, Volume 100C, A Review of Human Carcinogens. 2012; 100(C): 11-465.

<sup>25</sup> Acheson ED *et al.*, Mortality of two groups of women who manufactured gas masks from chrysotile and crocidolite asbestos: a 40-year follow-up. *Br J Ind Med* 1982; 39(4): 344-348.

<sup>26</sup> Magnani C, *et al.* Cancer risk after cessation of asbestos exposure: a cohort study of Italian asbestos cement workers. *Occup Environ Med* 2008;65(3): 164-170.

<sup>27</sup> Germani D, *et al.* Cohort mortality study of women compensated for asbestosis in Italy. *Am J Indus Med* 1999; 36(1): 129-134.

suggest that talc users would sustain asbestos exposure comparable to that of the women in these studies. By contrast, epidemiological studies of women who were exposed to asbestos in environmental, rather than occupational, settings have not shown a statistically significant association with ovarian cancer.<sup>28</sup>

### **Talc and Epithelial Ovarian Cancer**

The physical properties of talc, including anti-sticking, anti-caking, thickener, lubricant, carrier, and absorbency, explain its use in multiple commercial applications. Talc is utilized in the production of paint, polymers, paper, ceramics, animal feed, cosmetics, and pharmaceuticals. Occupational exposure to talc can occur from its mining and milling as well as from working in the multiple industries that use talc. Consumer exposure to talc typically occurs from the use of cosmetics, feminine hygiene products like body powders and sprays, and talc-containing pharmaceuticals. The patterns of use with regard to feminine hygiene products have been explored in multiple studies that examined the association between these products and ovarian cancer. Dusting of the genital area with powder is the predominant pattern of use; however, alternative patterns of use exist, including storage of diaphragms in talc and dusting of sanitary napkins. Studies that have a high prevalence of body powder use for feminine hygiene have attempted to quantify the frequency and duration of use, as well as the single or combination of patterns of use. What is clear is that women who use body powder for feminine hygiene typically do it daily and that it is a behavior that begins in early adulthood. The majority of women who use talc in the perineal area start use at around 20 years old.<sup>29</sup>

The literature examining the association between the use of talc-containing feminine hygiene products and ovarian cancer includes a fairly large number of studies of various designs. It is important to note the strengths and weaknesses of each study design and that these factors have led to a generally accepted hierarchy (*see* Figure 1) used to judge the strength of study results and the confidence we should have in them.

---

<sup>28</sup> Reid et al., Cancer incidence Among women and girls environmentally and occupationally exposed to blue asbestos at Wittenoom, Western Australia. *Int'l J Cancer* 2008; 122(1): 2337-2344.

<sup>29</sup> Cramer DW, et al., The association between talc use and ovarian cancer. *Epidemiology* 2016; 27: 334-336.




Figure 1. The Levels of Evidence. The Center for Evidence-Based Management (CEBMA)<sup>30</sup>

The concept of “levels of evidence” was first described in a report by the Canadian Task Force on the Periodic Health Examination in 1979<sup>31</sup> in an effort to rate the strength of evidence behind various practice recommendations. This original rating system has been adapted multiple times over the years but remains essentially unchanged. It ranks study designs largely by their risk of bias and systematic errors that increase the likelihood of erroneous conclusions. Prospective randomized controlled trials (RCTs), where study participants are randomly assigned to a particular intervention or exposure and followed prospectively for the outcome of interest, are generally considered the highest level of evidence because they are designed to be unbiased. Obviously, for studies of potential human carcinogens, a RCT is not always feasible or ethical, and alternative study designs are often utilized. In general, prospective cohort (or “longitudinal”) studies, where study participants are followed over years to determine the impact of a particular exposure, are considered superior to retrospective case-control (cross sectional) studies, where study participants with a particular disease are retrospectively queried about a particular exposure and the results compared to a control population of individuals who do not have the disease. While retrospective case-control studies are less expensive to complete and require significantly less time compared with cohort studies, they are plagued by weaknesses that explain their lower position in the levels of evidence hierarchy. Recall bias is a systematic error

<sup>30</sup> Center for Evidence-Based Management, What are the levels of evidence?. <https://www.cebma.org/faq/what-are-the-levels-of-evidence/> (last visited January 2019).

<sup>31</sup> The periodic health examination. Canadian Task Force on the Periodic Health Examination. *Can Med Assoc J.* 1979; 121: 1193-1254.

where the recall of past exposures or experiences differs between the patients with (cases) and those without (controls) the specific disease of interest. Multiple factors have been shown to impact the level of accuracy of recall of an exposure, including time since the exposure, the level of detail requested, personal characteristics such as educational level and socioeconomic status, and desirability of the recalled event/exposure.<sup>32</sup> Recall bias can lead to spurious results in case-control studies in a variety of clinical scenarios.<sup>33</sup> For these reasons, prospective cohort studies have more ability to accurately detect a causal relationship between an exposure and a particular disease. While case-control studies may generate hypotheses, their findings should ultimately be confirmed in a prospective manner. It should also be noted that combining the data from multiple studies that are potentially plagued with bias, like what is done in a meta-analysis, cannot overcome the inherent weaknesses of the original studies. The risk of an erroneous conclusion due to biased data persists.

The statement by plaintiffs' experts that epidemiological data overwhelmingly support an association between talc exposure and the development of ovarian cancer, much less a causal relationship, is patently false.<sup>34</sup> As I explain in the following section, no prospective cohort study with long-term follow up has shown an increased risk of ovarian cancer associated with cosmetic talc use. Moreover, roughly half of the retrospective case-control studies have come to the same conclusion. The erroneous conclusion that cosmetic talc use definitively increases the risk of ovarian cancer can only be reached by a selective reading of the body of literature on the topic and abandoning the well-accepted hierarchy defining the strength of the various study designs. A non-biased review of the epidemiology also explains why the United States Food and Drug Administration, which regulates talc use in the U.S., considers it generally safe for use as a food additive, in cosmetics, in pharmaceuticals, and in paper and paper products that come into contact with food.<sup>35</sup>

## **Human Studies on Cosmetic Talc Exposure**

### ***Case-Control Studies***

The first retrospective case-control study to implicate the use of talc-containing feminine hygiene products in the future development of ovarian cancer was published in 1982 by Cramer DW, *et al.*<sup>36</sup> The impetus for the study was the fact that talc was considered chemically similar to asbestos, which is known to cause mesothelioma, and the belief that talc applied to the genital area could be transported to the ovaries by passing through the uterus and fallopian tubes. In this study, 215 Boston-area white women with a history of EOC were compared with 215 controls

---

<sup>32</sup> Coughlin S. Recall bias in epidemiological studies. *J Clin Epidemiol* 1990; 43(1): 87-91.

<sup>33</sup> Schildkraut *et al.*, Association between body powder use and ovarian cancer: the African American cancer epidemiology study. *Cancer Epidemiol Biomarkers Prev* 2016; 25(10): 1411-1416.

<sup>34</sup> Expert Report of Daniel L. Clarke-Pearson, M.D. (filed Nov. 16, 2018) ("Clarke-Pearson Report") at 7; Expert Report of Dr. Judith Wolf, M.D. (filed Nov. 16, 2018) ("Wolf Report") at 8; Expert Report of Ellen Blair Smith, M.D. (filed Nov. 16, 2018) ("Blair Smith Report") at 16.

<sup>35</sup> Food and Drug Administration. Talc. U.S. Department of Health and Human Services, 2014. <http://www.fda.gov/Cosmetics/ProductsIngredients/Ingredients/ucm293184.htm>.

<sup>36</sup> Cramer DW, *et al.* Ovarian cancer and talc: a case-control study. *Cancer* 1982; 50(2): 372-376.

(matched for age, ethnicity and precinct of residence) with regard to their self-reported history of genital talc exposure. Two predominant modes of hygienic exposure to talcum powder were identified: use of talc as a dusting powder on the perineum and use of talc on sanitary napkins. Women who reported “any” prior use of genital talc were found to have a 92% increased risk of EOC compared with women reporting no prior exposure. Interestingly, women reporting use of talc by only one mode of exposure – dusting powder or on sanitary napkins – had only a borderline significant increased risk of EOC compared with controls. The weaknesses of this study design and the risk of unintended bias have already been addressed.

Since publication of the original Cramer study, there have been numerous case-control studies examining the relationship between any genital talc use and the risk of EOC. Table 1 provides a summary of these studies and demonstrates that roughly half show no significant increased risk for EOC associated with any genital talc use. It should be noted that in the studies that show a significantly increased risk, the risk estimates for any genital talc use and ovarian cancer are low and typically range between 1.2 and 1.6 (suggesting a 20%- 60% increased risk). Given that the odds ratios are so low, these results are unreliable and are likely nothing more than chance or the result of bias.

### ***Prospective Cohort Studies***

The first prospective cohort study to evaluate the risk of EOC associated with genital talc use was published by Gertig *et al.* in 2000.<sup>37</sup> This study included participants of a large study called the Nurses’ Health Study (“NHS”) that began in 1976 and prospectively followed 121,700 female registered nurses ranging in age from 30-55 years. Participants were sent questionnaires every two years that requested information about their medical history and risk factors for a number of diseases, including cancer and cardiovascular disease. In 1982, participants were queried about their history and frequency of application of body powder to the genital (perineal) area and/or application to sanitary napkins. The questionnaire specified frequency as none, daily, one to 6 days per week, and less than weekly. Seventy-eight thousand six hundred and thirty (78,630) women who responded comprised the study group. Forty percent of the respondents reported any use of talc in 1982, with 14.5% reporting daily use. Between 1982 and 1996, 307 women reported developing EOC and the diagnosis was confirmed by review of the medical records by a health care professional blinded to the exposure status of the participant. Overall, there was no significant increased risk of EOC seen in women reporting any use of talc for perineal dusting or application to sanitary napkins (relative risk 1.09, 95% confidence interval .86-1.37), and there was no increased risk of EOC seen in women with increasing frequency of applications (e.g., no dose-response relationship). Dr. Wolf testified that given the challenges of assessing dose, the evaluation of dose response in the epidemiology was not as important to her analysis,<sup>38</sup> but the fact that one cannot accurately assess dose does not diminish its importance in the assessment of causality. A modest increased risk was seen for the development of invasive serous ovarian cancer in women reporting any use of talc (relative risk 1.4, 95% confidence

---

<sup>37</sup> Gertig DM, Hunter DJ, Cramer DW, *et al.* Prospective study of talc use and ovarian cancer. *J Natl Cancer Inst* 2000; 92: 249-252.

<sup>38</sup> January 7, 2019 Deposition of Judith K. Wolf, M.D., at 332-33.

interval 1.02-1.91) and a borderline significant trend was seen for increasing risk and increasing frequency of use.

In 2010, Gates *et al.* reported a longer-term follow up of the NHS cohort utilized in the original Gertig study.<sup>39</sup> The purpose of this subsequent study was to evaluate the risk factors for the specific histologic types of EOC. Follow-up of participants through 2006 (10 years longer than the original study by Gertig DM, *et al.*) was high and included more than 95% of participants. Overall, the study findings supported the concept that the various histologic types of EOC carry distinct reproductive and environmental risk factors. Importantly, there was no increased risk of serous carcinoma associated with genital talc use seen, reversing the finding of the only prospective cohort study reporting an association between genital talc use and EOC.

Houghton SC, *et al.*, utilized the Women's Health Initiative ("WHI") participants to examine perineal powder use and the risk of ovarian cancer.<sup>40</sup> The WHI was a large prospective study that enrolled more than 93,000 postmenopausal women aged 50-79 between 1993 to 1998. Participants were mailed annual questionnaires that collected information on risk factors and outcomes, including ovarian cancer. After applying appropriate exclusions, the final study population was comprised of 61,576 participants and 429 incident ovarian cancers that developed over a mean follow-up of 12.4 years. Use of genital talc was assessed at baseline with the question, "Have you ever used powder on your private parts (genital areas)?" Respondents responding yes were then asked to identify their duration of use (less than 1 year, 1-4 years, 5-9 years, 10-19 years, or >20 years). Similar assessments were done for women reporting use on a diaphragm and those reporting use on sanitary napkins or pads. Approximately half of the study population reported ever using perineal talc (52.6%), and there was no statistically significant association between the use of genital talc and the development of ovarian cancer for ever-users (HR 1.13; CI 0.93,1.37). The use of powder on sanitary napkins or diaphragms was also not associated with an increased risk of ovarian cancer. Plaintiffs' experts take issue with the short follow-up period of the study;<sup>41</sup> however, there was no association with the duration of use and the future development of ovarian cancer and no increased risk for women who reported genital use of talc for 20 years or more (HR 1.10; CI 0.82,1.48). Women were also followed for a mean of 12.4 years after reporting use of talc for 20 years or more. Finally, a subset analysis showed no significantly increased risk specifically for serous adenocarcinoma in women reporting any use of perineal powder (hazard ratio 1.16, 95% CI .88,1.53).

The Sister Study, the most recent prospective cohort study to examine the potential relationship between genital talc use and ovarian cancer, was published by Gonzalez NL, *et al.* in 2016.<sup>42</sup> This study was started in 2003 and prospectively followed 41,654 women aged 35 to 74 in the US and Puerto Rico. Each participant had no prior breast cancer but had a full or half-sister with a history of breast cancer. Upon study entry, each participant was queried about reproductive

---

<sup>39</sup> Gates, *et al.* Risk factors for epithelial ovarian cancer by histologic subtype. *Am J Epidemiol* 2010; 171: 45-53. <http://doi.org/10.1093/aje/kwp314>.

<sup>40</sup> Houghton SC, *et al.* Perineal powder use and risk of ovarian cancer. *J Natl Cancer Inst* 2014; 106(9): dju208.

<sup>41</sup> January 9, 2019 Deposition of Ellen Blair Smith, M.D., at 244:7-16; January 7, 2019 Deposition of Judith K. Wolf, M.D., at 288:19-289:4; Wolf Report at 7.

<sup>42</sup> Gonzalez NL, *et al.* Douching, talc use, and risk of ovarian cancer. *Epidemiology* 2016; 27(6): 797-802.

history, health conditions and the use of personal care products (including use of perineal powders and sprays as well as douching) over the 12 months prior to enrollment. Information on the frequency of use was stratified as none, less than twice per month, 1-3 times per month, or more than 5 times per week. Follow-up questionnaires were administered every two years through 2009 and updated information on any cancers that developed. The risk for the development of EOC was calculated for talc exposure exclusively, douching exclusively, and for the combination of both exposures. During a median follow up of 6.6 years, 154 participants reported a diagnosis of ovarian cancer. The results showed that douching, not perineal talc use, significantly increased the risk of ovarian cancer. The hazard ratio for talc and ovarian cancer was .73 (95% confidence interval .44-1.2), while the hazard ratio for douching and ovarian cancer was 1.8 (95% confidence interval 1.2-2.8). With respect to the short follow-up in this study, one must consider that the women likely started their talc use years prior to enrollment in the study.<sup>43</sup>

Interestingly, the Sister Study found that women who used talc were twice as likely to douche. This finding is significant because it identifies douching as a potential confounder that was not controlled for in most prior case-control studies. If douching increases the risk of ovarian cancer and women who use talc are also more likely to douche (as demonstrated in The Sister Study), a case-control study could easily identify an association between talc use and ovarian cancer when no causal relationship exists. This would not be the first time this occurred in the epidemiology of human cancers. Since the end of the 1960s, Herpes Simplex Virus (“HSV”) was thought to be the main cause of invasive cervical cancer, largely based on a series of case-control studies showing a significant association.<sup>44,45</sup> Fortunately, subsequent prospective studies demonstrated no significant association between HSV and cervical cancer<sup>46</sup> and improvements in the detection of Human Papilloma Virus (“HPV”) led to its identification of the true cause of invasive cervical cancer.<sup>47</sup> In retrospect, the case-control studies that initially identified an association between Herpes Virus and cervical cancer were biased because they did not control for HPV infection. Had the scientific community persisted in its belief that HSV caused cervical cancer, it is unlikely that prophylactic HPV vaccines, which have the potential to save millions of lives worldwide, would have ever been developed.

---

<sup>43</sup> Cramer DW, *et al.*, The association between talc use and ovarian cancer. *Epidemiology* 2016; 27:334-336; Wu, A, *et al.* African Americans and Hispanics remain at lower risk of ovarian cancer than non-Hispanic whites after considering nongenetic risk factors and oophorectomy rates. *Cancer Epidemiol Biomarkers Prev* 2015; 24(7): 1094-1100.

<sup>44</sup> Rawls WE, Adam E, Melnick JL. An analysis of seroepidemiological studies of herpes virus type 2 and carcinoma of the cervix. *Cancer Res* 1972; 33:1479-1482.

<sup>45</sup> Nahmias AJ, Josey WE, Naib ZM, *et al.* Antibodies to herpesvirus hominis types 1 and 2 in humans. II. Women with cervical cancer. *Am J Epidemiol* 1970; 91: 547-552.

<sup>46</sup> Vonka V, Kanka J, Jelinek I, *et al.* Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. *Int J Cancer* 1984; 33: 61-68.

<sup>47</sup> Lehtinen M, *et al.* Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the nordic countries. *Am J Epidemiol* 2002; 156(8): 687-692.

### *Meta-analyses*

A meta-analysis is a systematic review of data, carried out under strict criteria, that pools the data from multiple studies for a single quantitative analysis. The technique can provide useful information by increasing the sample size available to study a particular clinical question, but unfortunately has multiple caveats regarding the conduct and interpretation that increase the possibility of misleading results. Even small deviations from the rules defining the conduct of a meta-analysis can have a profound impact on the validity of the conclusions, and this is why the technique is considered potentially powerful but remains controversial. There are four critical principles of meta-analyses that must be considered: identification and selection of the included studies, heterogeneity among the results of the included studies, availability of the information, and analysis of the data. Numerous meta-analyses have been performed examining the impact of genital talc exposure and the risk of ovarian cancer and have come to discrepant results.

Terry KL, *et al.* published their pooled analysis examining the impact of genital powder (not specifically talc) use and ovarian cancer risk in 2013.<sup>48</sup> The study included data from eight case-control studies contributing a total of 8,525 ovarian cancer cases and 9,859 controls for the pooled analysis. The study found a modest increased risk of ovarian cancer associated with genital talc use (odds ratio 1.24, 95% confidence interval 1.15-1.33). Risk was increased for cancers of serous, endometrioid, and clear cell varieties. Interestingly, no relationship between the number of lifetime applications and risk of ovarian cancer was identified (i.e., no dose-response relationship), and there was no increased risk for women who reported only non-genital powder use. Despite this analysis being performed after the publication of two prospective cohort studies evaluating genital powder use and ovarian cancer risk (Gertig *et al.* and Gates *et al.*), neither of these studies was included in the analysis. This is because the analysis was restricted to studies from the Ovarian Cancer Association Consortium, a group founded in 2005 to validate promising genetic associations in epidemiologic studies of ovarian cancer. This represents an informative example of the “study selection bias” that plagues many meta-analyses and weakens confidence in the results. No explanation for the restriction was offered by the authors, and it is not mentioned as a weakness in the discussion section.

In 2018, Berge *et al.* published their meta-analysis evaluating genital use of talc and the risk of ovarian cancer.<sup>49</sup> The authors ultimately identified 24 case-control studies, three cohort studies and one pooled analysis of eight of the 24 case-control studies. Significant heterogeneity was identified between the case-control and cohort trials. When combining the studies of both designs together, the authors found a weak, but statistically significant, increased association between genital talc use and ovarian cancer (relative risk 1.22, 95% confidence interval 1.13,1.30). This association was limited to serous carcinoma and no association was noted for the other histologic types. The authors noted a weak trend in risk ratio with regard to increasing duration or frequency of talc use. When the case-control studies were separated from the prospective cohort trials, however, the significant association was found only in the case-control

---

<sup>48</sup> Terry KL, *et al.* Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. *Cancer Prev Res* 2013; 6(8): 811-821.

<sup>49</sup> Berge, W, *et al.* Genital use of talc and risk of ovarian cancer: a meta-analysis. *Eur J Cancer Prev* 2018; 27: 248-257.

studies (relative risk 1.26, 95% confidence interval 1.17-1.35). The prospective cohort studies showed no association between genital talc and ovarian cancer (relative risk 1.02, 95% confidence interval .85-1.2). As mentioned earlier, combining the results of studies with significant heterogeneity between them into a single meta-analysis increases the likelihood of spurious results. For this reason, the authors cautioned that “[t]he heterogeneity of results by study design however, detracts from a causal interpretation of this association.”<sup>50</sup>

One of the largest meta-analyses on which plaintiffs’ experts rely<sup>51</sup> in evaluating ovarian cancer and genital talc use is the study by Penninkilampi and Eslik.<sup>52</sup> The data extraction section of the publication states that Penninkilampi is the person who performed the data extraction, assessed the quality of the studies using the Newcastle-Ottawa Scale (NOS), and calculated the unadjusted ORs and CIs when not reported in the original publications. It should be noted that the lead author, Ross Penninkilampi, is still a medical student at UNSW Australia. Some of the data extraction is simply wrong. For example, for Chen (1992), the authors report an OR of 3.90 (CI 1.43-10.60) (statistically significant); however, the actual paper reports an OR of 3.90 (CI 0.9-10.60) (not statistically significant).<sup>53</sup> In addition, Penninkilampi reports the range of NOS ratings of the included studies as ranging from 5/10 to 8/10 when the NOS has a maximum score of 9, not 10. The authors queried six electronic databases for observational studies with greater than 50 ovarian cancer cases and selected 24 case-control studies (13,421 ovarian cancer cases) and three prospective cohort studies (890 ovarian cancer cases) for the analysis. The authors found that “any” genital talc use was associated with an increased risk of ovarian cancer (odds ratio 1.31, 95% confidence interval 1.24-1.39) and that >3600 lifetime applications (approximately 10 years of daily use) were associated with a “slightly” increased risk of ovarian cancer than <3600 applications. This association was only seen in serous and endometrioid varieties of ovarian cancer. Not surprisingly, the association with any genital talc use and ovarian cancer was found exclusively in case-control studies and not in prospective cohort studies, although the authors report that a significant increase in the risk of serous ovarian cancer specifically was found in cohort studies (OR 1.25, 95% confidence interval 1.01-1.55).

I found this study particularly interesting because of the authors’ focus on the medical-legal aspects of the study question. To justify the need for the study, the authors state, “...the association between talc use and ovarian cancer takes on considerable relevance, as the pharmaceutical and consumer products company Johnson & Johnson has recently had damages levied to the total of US\$717 million dollars against them in five law suits.”<sup>54</sup> Also peculiar is the

---

<sup>50</sup> Berge, W, *et al.* Genital use of talc and risk of ovarian cancer: a meta-analysis. *Eur J Cancer Prev* 2018; 27: 248-257.

<sup>51</sup> For example, the Penninkilampi and Eslik study is the only meta-analysis study analyzed by Dr. Wolf. Wolf Report at 8.

<sup>52</sup> Penninkilampi, R and Eslik, GD. Perineal talc use and ovarian cancer: a systematic review and meta-analysis. *Epidemiology* 2018; 29: 41-49.

<sup>53</sup> Chen, Y, *et al.* Risk factors for epithelial ovarian cancer in Beijing, China. *Intl J Epidemiol* 1992; 21(1): 23-29.

<sup>54</sup> Penninkilampi, R and Eslik, GD. Perineal talc use and ovarian cancer: a systematic review and meta-analysis. *Epidemiology* 2018; 29: 41-49.

exclusion of the updated data from the NHS prospective cohort study by Gates *et al.*<sup>55</sup> that reversed the findings of the initial study by Gertig *et al.* showing an increased risk of serous ovarian cancer with any talc use. Inclusion of this study would have certainly negated the reported finding of an increased risk of serous carcinoma in cohort studies and could have potentially impacted the results in general. While the Gates *et al.* study clearly met the inclusion criteria for the current meta-analysis and is of a stronger level of evidence than the majority of included studies, its title was not identified by the search terms chosen by Penninkilampi and Eslik.<sup>56</sup> This is a clear example of “study identification bias,” another deviation from the principles of meta-analyses that can lead to misleading results.

Overall the meta-analyses offer little new information regarding the association between genital talc use and ovarian cancer. Some case-control studies suggest a modest increased risk of ovarian cancer, while the higher-level prospective-cohort studies uniformly do not. Adding them together does not alter this reality.

Despite these limitations of meta-analyses, plaintiffs’ experts rely heavily on them to support their position. Dr. Clarke-Pearson, in fact, states that “[w]hile recent case-control studies and cohort studies are compelling, I feel that meta-analysis studies are much stronger in that they include larger numbers of patients resulting in greater statistical power.”<sup>57</sup> Dr. Blair Smith similarly states that in her opinion, “meta-analysis is the most valid and reliable way to study an issue like ovarian cancer,” although she acknowledges that meta-analysis does not eliminate the possibility of recall bias in the underlying studies.<sup>58</sup>

### **The Talc Theory**

While the available epidemiological data do not support a definitive association, much less a causal relationship, between talc exposure and ovarian cancer, an examination of the data surrounding the carcinogenic potential of talc is worthwhile. This includes questions regarding the ability of talc particles to reach the ovaries and peritoneal cavity, the modes by which this may happen, and the proposed mechanisms of how they initiate or promote cancer once there. Although Drs. Blair Smith, Wolf and Clarke-Pearson opine – without citation to any study showing a relationship between inhalation of talc and ovarian cancer – that inhalation is a secondary route of exposure,<sup>59</sup> the epidemiologic data on talc do not support inhalation as

---

<sup>55</sup> Gates, *et al.* Risk factors for epithelial ovarian cancer by histologic subtype. *Am J Epidemiol* 2010; 171: 45-53. <http://doi.org/10.1093/aje/kwp314>.

<sup>56</sup> Penninkilampi R., *et al.* Perineal talc use and ovarian cancer: a systematic review and meta-analysis. *Epidemiology* 2018; 29(1): 41-49.

<sup>57</sup> Clarke-Pearson Report at 7.

<sup>58</sup> Blair Smith Report at 16; January 9, 2019 Deposition of Ellen Blair Smith, M.D., at 236-237.

<sup>59</sup> Blair Smith Report at 22; Wolf Report at 11; Clarke-Pearson Report at 8. In fact, Dr. Wolf cites to Cramer *et al.* 2007, where the authors explicitly stated that “[w]e are not claiming that a causal relationship between ovarian cancer and talc use is proven for this case or in general.” Cramer DW, *et al.* Presence of talc in pelvic lymph nodes of a woman with ovarian cancer and long-term genital exposure to cosmetic talc. *Obst Gyn* 2007; 110(2): 498-501 (cited in Wolf Rep. at 11). Similarly, Dr. Clarke-Pearson relies on Steiling 2018 (Clarke-Pearson Report at 8), yet conceded at his deposition that the paper says nothing about inhaled particles migrating to the ovaries – or anywhere – and to date “we haven’t seen an increased risk of ovarian cancer . . . with inhaled talcum powder.” February 4,

associated with an increased risk of ovarian cancer. The case-control studies that suggest a modest increased risk of ovarian cancer with talc exposure do not show an increased risk with “body-only” use. As such, the viability of their theory depends on the ability of talc to ascend through the female genital tract.

### **Migration of Talc Particles**

Plaintiffs’ experts take as a given that talc particles can ascend the female genital tract, when in fact, data from animal studies on this issue are inconsistent (indeed, IARC determined that the evidence of retrograde talc transport is “weak”).<sup>60</sup> For example, Wehner *et al.* placed talc directly into the upper vagina of sedated cynomolgus monkeys on 30 occasions over a 45-day period, and the authors were unable to detect the radiolabeled talc in the uterus or higher in any animal.<sup>61</sup> In contrast, Henderson *et al.* placed a suspension of talc particles into the vaginas and uteri of eight Sprague-Dawley rats and found talc particles in the ovaries of all the rats that received intrauterine talc injections and in the rats that received intravaginal instillations of talc and sacrificed after four days.<sup>62</sup> With regard to human studies, Heller *et al.* examined the ovaries of 24 women undergoing surgical removal of the ovaries, 12 of whom reported frequent use of genital talc products.<sup>63</sup> The presence of talc was examined by polarized light and electron microscopy. Interestingly, talc particles were found in all 24 women, regardless of talc exposure history, and particle counts were completely unrelated to reported levels of genital talc exposure. In fact, higher talc particle levels were found in women with no reported talc exposure. These findings call into question the mode of exposure of the ovaries to talc particles, raise the potential of contamination during specimen handling, and call into question the clinical significance of talc particles that may be identified in the pathologic specimens of patients with ovarian cancer. As noted by Dr. Wolf,<sup>64</sup> Cramer *et al.* identified talc particles in the pelvic lymph nodes of a 68-year-old woman with stage III ovarian cancer using polarized and electron microscopy.<sup>65</sup> Interestingly, the reported patient was stage III because of metastatic disease in her right pelvic nodes, and yet talc particles were only found in left pelvic lymph nodes that did not contain cancer.

Additionally, if ascension of talc particles through the female genital tract is essential in its ability to cause/promote ovarian cancer, one would expect a protective effect from procedures like tubal ligation or hysterectomy that block this mode of exposure. Dr. Blair Smith testified

---

2019 Deposition of Daniel L. Clarke-Pearson, M.D., at 218:13-219:23; Steiling W, *et al.* Principles for the safety evaluation of cosmetic powders. *Toxicology Letters* 2018; <https://doi.org/10.1016/j.toxlet.2018.08.011>.

<sup>60</sup> January 9, 2019 Deposition of Ellen Blair Smith, M.D., at 262:9-263:19; January 7, 2019 Deposition of Judith K. Wolf, M.D., at 191:21-192:3; IARC Talc Monograph at 411.

<sup>61</sup> Wehner AP, Weller RE, Lepel EA. *Food Chem Toxicol* 1986; 24(4): 329-338.

<sup>62</sup> Henderson WJ, *et al.* The demonstration of the migration of talc from the vagina and posterior uterus to the ovary in the rat. *Environ Research* 1986; 40: 247-250.

<sup>63</sup> Heller DS, *et al.* Asbestos exposure and ovarian fiber burden. *Am J Ind Med* 1996; 29: 435-439.

<sup>64</sup> Wolf Report at 11.

<sup>65</sup> Cramer DW, *et al.* Presence of talc in pelvic lymph nodes of a woman with ovarian cancer and long-term genital exposure to cosmetic talc. *Obst Gyn* 2007; 110(2): 498-501.

that she finds the tubal ligation data consistent;<sup>66</sup> however, tubal ligation has not proven protective in multiple studies examining the association between genital talc use and ovarian cancer, including the prospective cohort study of the NHS participants (Gertig *et al.*)<sup>67</sup> as well as the meta-analysis by Terry KL, *et al.*<sup>68</sup> In addition, as Dr. Blair Smith admitted in her deposition, some analyses limited to modes of exposure that ensure internal deposition of the talc particles, like dusting of diaphragms<sup>69</sup> or condoms<sup>70</sup> show no increased risk of ovarian cancer with these behaviors.<sup>71</sup>

### **Talc and Ovarian Cancer Carcinogenesis**

Talc has not proven genotoxic to normal cells, and there is speculation regarding just how it potentially causes cancer. One theory set forth by plaintiffs' experts is that chronic inflammation caused by talc particles either initiates or promotes carcinogenesis.<sup>72</sup> The carcinogenesis of ovarian cancer is poorly understood overall, and the potential that chronic inflammation plays a role has been examined in a number of settings. The studies that analyze whether the risk of ovarian cancer is increased in women with a history of pelvic inflammatory disease ("PID") are inconsistent.<sup>73</sup>

In addition, there are inconsistent data – as plaintiffs' experts admit<sup>74</sup> – suggesting a possible protective effect of chronic non-steroidal anti-inflammatory drug ("NSAID") use against the future development of ovarian cancer. For example, Bonovas *et al.* is a meta-analysis that showed anti-inflammatory drug use did not reduce ovarian cancer risk.<sup>75</sup> Ni *et al.*, a pooled analysis of 13 case-control studies, one clinical trial and three cohort studies, also found no evidence of an association between aspirin use and ovarian cancer and did not find strong

---

<sup>66</sup> January 9, 2019 Deposition of Ellen Blair Smith, M.D., at 268-269.

<sup>67</sup> Gertig DM, Hunter DJ, Cramer DW, *et al.* Prospective study of talc use and ovarian cancer. *J Natl Cancer Inst* 2000; 92: 249-252.

<sup>68</sup> Terry KL, *et al.* Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. *Cancer Prev Res* 2013; 6(8): 811-821.

<sup>69</sup> Huncharek, *et al.* Use of Cosmetic talc on contraceptive diaphragms and risk of ovarian cancer: a meta-analysis of nine observational studies. *Eur J Cancer Prev* 2007; 16: 422-429; Cramer DW, *et al.* Ovarian cancer and talc: a case-control study. *Cancer* 1982; 50(2): 372376 (Table 2 shows diaphragm use association was not statistically significant).

<sup>70</sup> Rosenblatt KA., *et al.* Mineral fiber exposure and the development of ovarian cancer. *Gyn Onc* 1992; 45: 20-25 (Table 3 shows condom use association was not statistically significant: OR 1.6 (CI 0.6-3.9)); Cramer DW, *et al.* Ovarian cancer and talc: a case-control study. *Cancer* 1982; 50(2): 372376 (Table 2 shows condom use association was not statistically significant: adjusted RR 0.77 (0.41-1.44)).

<sup>71</sup> January 9, 2019 Deposition of Ellen Blair Smith, M.D., at 296.

<sup>72</sup> Blair Smith Report at 17-18; Wolf Report at 9; Clarke-Pearson Report at 4.

<sup>73</sup> Zhou Z, *et al.* Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis. *Cancer Causes Control* 2017 May; 28(5): 415-428; Rasmussen, CB, *et al.* Is pelvic inflammatory disease a risk factor for ovarian cancer? *Cancer Epidemiol Biomarkers Prev* 2017; 26(1): 104-109.

<sup>74</sup> Blair Smith Report at 18; Wolf Report at 12.

<sup>75</sup> Bonovas S, *et al.* Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. *Br J Clin Pharmacol* 2005; 60(2): 194-203.

evidence of an association between non-aspirin NSAID use and ovarian cancer.<sup>76</sup> On the other hand, Trabert *et al.* did report a modest risk reduction for aspirin use but found no risk reduction for NSAID use.<sup>77</sup> The authors conducted another study this year and also reported a modest decrease in risk reduction for aspirin use, but no risk reduction for other types of anti-inflammatories.<sup>78</sup> In clinical practice, NSAIDs are not recommended as a means to reduce the risk of ovarian cancer (unlike oral contraceptives).

There is no doubt that talc can induce a local inflammatory response in sufficient doses. In fact, this inflammatory response has been recognized for decades and led to one of the most common medical indications for talc: pleurodesis. Pleurodesis involves the direct injection of .5 to 10 grams of talc directly into the cavity surrounding the lungs (pleural cavity) in hopes of stimulating a strong inflammatory reaction that would cause scarring of the lung to the pleura and obliteration of potential space for air (pneumothorax) or fluid (pleural effusion). The procedure has been practiced since the 1930s.<sup>79</sup> It is important to recognize the biological similarities between the pleura and the peritoneum (the membrane lining the pelvic cavity that contains the fallopian tubes and ovaries). Both tissues are composed of mesothelial cells, both membranes protect internal organs and produce small amounts of lubricating fluid, and both can potentially undergo malignant transformation in the presence of carcinogens. Chronic asbestos exposure causes both pleural and peritoneal malignant mesothelioma, its hallmark cancers. Pleurodesis, therefore, offers years of clinical experience with which to examine the malignant potential of talc on mesothelial cells, cells that are very similar to those accepted as the origin of epithelial ovarian cancer. In 1979, a report was issued by the Research Committee of the British Thoracic Association on the long-term effects of pleurodesis using talc and kaolin in a group of patients with follow-up from 14 to 40 years.<sup>80</sup> Among 210 patients who underwent the procedure, there were three cases of lung cancer that developed in the cohort (not statistically increased above expected). Two of these cancers occurred on the opposite side of the chest than the talc pleurodesis and no patient developed malignant mesothelioma.<sup>81</sup> Another study of 99 Danish patients who underwent pleurodesis between 1954 and 1964 and were followed for at least 20 years was published by Viksum *et al.*<sup>82</sup> Three cases of lung cancer occurred over the period of follow-up with one occurring in the contralateral lung not exposed to talc. Again, no cases of malignant mesothelioma occurred. Additionally, Györik *et al.* conducted a follow-up

---

<sup>76</sup> Ni X, *et al.* Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer. *Br J Clin Pharmacol* 2012; 75(1): 26-35.

<sup>77</sup> Trabert B, *et al.* Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the ovarian cancer association consortium. *J Natl Cancer Inst* 2014; 106(2): 1-11.

<sup>78</sup> Trabert, *et al.* Analgesic use and ovarian cancer risk: an analysis in the ovarian cancer cohort consortium, *J. Nat'l Cancer Inst.* (2019) 111(2): 137-145, 139-42.

<sup>79</sup> IARC Monograph. Carbon black, titanium dioxide, and talc. 2010; 93: 1-413, pg. 378.

<sup>80</sup> Research Committee of the British Thoracic Association and the Medical Research Council Pneumoconiosis Unit; Research Counsel Pneumoconiosis. A survey of the long-term effects of talc and kaolin pleurodesis. *Br J Dis Chest* 1979; 73: 285-88.

<sup>81</sup> IARC Monograph. Carbon black, titanium dioxide, and talc. 2010; 93: 1-413, pg. 379.

<sup>82</sup> Viksum K, *et al.* Long term sequelae after talc pleurodesis for spontaneous pneumothorax. *Pneumologie* 1989; 43: 105-106.

study in 63 patients with primary spontaneous pneumothorax who underwent talc pleurodesis.<sup>83</sup> One case of bronchogenic carcinoma was noted in a smoker, but no cases of malignant mesothelioma occurred. Talc remains the most commonly used sclerosing agent for pleurodesis worldwide.<sup>84</sup> Rather than data suggesting talc causes cancer of the pleura, a recent randomized controlled trial suggested it actually induces cancer cell death in patients with mesothelioma, leading to improved survival.<sup>85</sup>

### **Evaluating Causation**

In 1965, Austin Bradford Hill<sup>86</sup> described the nine criteria that should be met to determine whether there is a causal relationship between an exposure and a disease. The nine “Bradford Hill” criteria are strength of association, consistency, temporality, dose-response, biologic plausibility, coherency, specificity, experimental evidence, and analogy.

The strength of association, which is determined by the risk estimates found in longitudinal and cross-sectional studies, is the first criterion. The higher the risk-estimate, the higher the likelihood that a causal relationship between the exposure and the disease exists. The lower the risk estimate, the higher the likelihood that the association is due to a confounding variable and that the association is spurious. Risk estimates (relative risks for case-control studies and hazard or odds ratios for prospective studies) are then further scrutinized to determine the range for which there is 95% certainty that the true risk estimate lies. This is called a 95% confidence interval (CI) and if the range crosses 1, the finding is not considered statistically significant regardless of whether the risk appears to be increased or decreased by a particular exposure.

Plaintiffs’ experts emphasize the significance of the slight increased risks found in the case-control studies. For example, both Drs. Wolf and Clarke-Pearson find a 30-40% increase in risk (RR 1.3-1.4) to satisfy the criteria of strength of association.<sup>87</sup> But an increased risk of this level is generally considered to be either a weak association or no association at all; in fact, Hill used examples where the increased risk was ten-fold and even greater in illustrating this factor.<sup>88</sup> By way of comparison, risk estimates for ovarian cancer associated with talc use from case-control studies show less than a two-fold increased risk, while the estimates of the relative risk of lung cancer in the long-term smokers compared with the lifetime nonsmoker vary from 10- to 30-fold.

---

<sup>83</sup> Györik, *et al.* Long-term follow-up of thoroscopic talc pleurodesis for primary spontaneous pneumothorax. *Eur. Resp J* 2007; 29(4): 757-760.

<sup>84</sup> Korsic M, *et al.* Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study. *Wien Klin Wochenschr (Central Eur J Med)* 2015; 127: 963-969.

<sup>85</sup> Davies HE, Mishra EK, Kahan BC, *et al.* Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. *JAMA* 2012; 307(22): 2383-2389; Nasreen N, *et al.* Talc induces apoptosis in human malignant mesothelioma cells in vitro. *Am J Respir Crit Care Med* 2000; 161: 595-600.

<sup>86</sup> Hill A. Environment and disease: association or causation? *Proc Royal Soc Med* 1965; 58: 295-300.

<sup>87</sup> Wolf Report at 6, 14; Clarke-Pearson Report at 6.

<sup>88</sup> Hill A. Environment and disease: association or causation? *Proc Royal Soc Med* 1965; 58: 295-300.

Comparatively, the presence of Human Papilloma Virus is associated with a 50-100-fold increased risk of cervical cancer.<sup>89</sup> The case-control studies involving talc therefore fail to satisfy the strength-of-association criterion.

**Table 2.** Adjusted ORs for the associations between mode, frequency, and duration of body powder use and ovarian cancer in the AACES

Exposure	Cases (n = 584) n (%)	Controls (n = 745) n (%)	OR* (95% CI)
Body powder use			
Never use	217 (37.2)	351 (47.1)	1.00 (Referent)
Ever use	367 (62.8)	394 (52.9)	1.39 (1.10–1.76)
Body powder use by location			
Never use	217 (37.2)	351 (47.1)	1.00 (Referent)
Only nongenital use	119 (20.4)	140 (18.8)	1.31 (0.95–1.79)
Any genital use	248 (42.5)	254 (34.1)	1.44 (1.11–1.86)
Interview date <2014 (n = 351)		(n = 571)	
Never use	147 (41.9)	286 (48.4)	1.00 (Referent)
Only nongenital use	76 (21.7)	104 (17.6)	1.40 (0.96–2.03)
Any genital use	128 (36.5)	201 (34.0)	1.19 (0.87–1.63)
Interview date >2014 (n = 233)		(n = 154)	
Never use	70 (30.0)	65 (42.2)	1.00 (Referent)
Only nongenital use	43 (18.4)	36 (23.3)	1.26 (0.69–2.32)
Any genital use	120 (51.5)	53 (34.4)	2.91 (1.70–4.97)
Frequency of use			
Never use	217 (37.3)	351 (47.2)	1.00 (Referent)
Only nongenital use			
Less than daily	61 (10.5)	82 (11.0)	1.15 (0.78–1.71)
Daily	58 (10.0)	58 (7.8)	1.53 (1.00–2.35)
P <sub>trend</sub>			0.09
Any genital use			
Less than daily	88 (15.1)	119 (16.0)	1.12 (0.80–1.58)
Daily	158 (27.2)	134 (18.0)	1.71 (1.26–2.33)
P <sub>trend</sub>			<0.01
Duration of use			
Never use	217 (37.4)	351 (47.4)	1.00 (Referent)
Only nongenital use			
<20 years	59 (10.2)	68 (9.2)	1.37 (0.91–2.07)
>20 years	60 (10.3)	70 (9.5)	1.28 (0.85–1.93)
P <sub>trend</sub>			0.13
Any genital use			
<20 years	101 (17.4)	118 (15.9)	1.33 (0.95–1.86)
>20 years	144 (24.8)	134 (18.1)	1.52 (1.11–2.07)
P <sub>trend</sub>			0.02
Lifetime body powder applications			
Never use	217 (37.4)	351 (47.4)	1.00 (Referent)
Only nongenital use			
Below median (<3,600 applications)	60 (10.3)	72 (9.7)	1.35 (0.90–2.03)
Above median (>3,600 applications)	59 (10.2)	66 (8.9)	1.30 (0.86–1.97)
P <sub>trend</sub>			0.14
Any genital use			
Below median (<3,600 applications)	92 (15.9)	119 (16.1)	1.16 (0.83–1.63)
Above median (>3,600 applications)	152 (26.2)	133 (17.9)	1.67 (1.23–2.26)
P <sub>trend</sub>			<0.01

\*Adjusted for age at diagnosis/interview, study site, education, tubal ligation parity, BMI, duration of OC use, first-degree family history of breast or ovarian cancer, and interview year.

The consistency found among various studies of different types is also a very important consideration. As set forth above in my discussion of the epidemiological studies, the results of the studies are inconsistent. In particular, approximately half of the case-control studies and all of the cohort studies found no significant increased risk of EOC from genital talc use. Plaintiffs' experts essentially ignore this inconsistency in the data, and in fact, tout the supposed consistency of the studies.<sup>90</sup> For example, Dr. Clarke-Pearson does not even discuss the cohort studies in his report, instead focusing on just the case-control studies (and nowhere mentioning that approximately half of those studies found no significant increased risk for EOC from talc use). Dr. Wolf opined in her report that she "found the most recent [case-control studies] to be the most useful based on their size and quality of design."<sup>91</sup> As demonstrated in the Schildkraut publication, the litigation publicity post-2014 may have affected the ORs due to the potential for recall bias. Talc exposure was similar in both cases and controls prior to 2014, and diverge only after that year.<sup>92</sup> Drs. Clarke-Pearson, Wolf and Blair Smith all dismiss the cohort studies in favor of meta-analyses, ignoring the fact that these studies simply reuse the same data.<sup>93</sup>

The studies also fail to show a consistent dose-response relationship, whereby increasing levels of exposure are associated with increased risk of

<sup>89</sup> Bosch FX, *et al.* The causal relation between human papillomavirus and cervical cancer. *J Clin Pathol* 2002; 55(4): 244-265.

<sup>90</sup> January 7, 2019 Deposition of Judith K. Wolf, at 254-55; Wolf Report at 20; Clarke-Pearson Report at 6.

<sup>91</sup> Wolf Report at 6-7 (citing Wu 2015, Cramer 2016, and Schildkraut 2016).

<sup>92</sup> Schildkraut *et al.* Association between body powder use and ovarian cancer: the African American cancer epidemiology study. *Cancer Epidemiol, Biomarkers Prev* 2016; 25(10): 1411-1416, at Table 2.

<sup>93</sup> Clarke-Pearson Report at 7; Wolf Report at 8; Blair Smith Report at 16.

ovarian cancer. For example, Drs. Wolf and Clarke-Pearson cite to the 2016 Cramer study in asserting that risk of EOC increases with frequency and duration of use.<sup>94</sup> Cramer reported an increased risk of EOC based on total lifetime applications of talc, finding that there was a statistically significant risk from 1-5 years of daily use (RR 1.38, 95% confidence interval 1.01-1.88), and after the equivalent of more than 20 years of daily use (RR 1.49, 95% confidence interval 1.06-2.10). However, women who reportedly used talcum powder for the equivalent of between 5-20 years did not have a statistically significant increased risk (RR 1.16, 95% confidence interval .80-1.66). Drs. Wolf and Clarke-Pearson also point to the Schildkraut study as support for the same point that risk increases with duration and frequency of talc use. The Schildkraut study, however, only reported the difference in risk between women who had used talc for less than 20 years and 3,600 applications and more than 20 years and 3,600 applications.<sup>95</sup> Therefore, demonstrating a trend in dose-response is not possible given that there were only two data points. Moreover, there have been a number of case-control studies that reported no dose-response relationship. For example, Cook *et al.* assessed cumulative lifetime days for various types of exposure, including perineal dusting.<sup>96</sup> There was no statistically significant elevated risk for any of the types of exposure examined. The relative risk for the group with fewer than 2,000 cumulative days of use (RR 1.8, 95% confidence interval 0.9-3.5) reported essentially matching risk estimates as the group with greater than 10,000 cumulative days of use (RR 1.8, 95% confidence interval 0.9-3.4). Mills *et al.* examined frequency and duration of use by quartiles, reporting risks of 1.03, 1.81, 1.74 and 1.06 for ascending quartiles.<sup>97</sup> The authors concluded that a dose-response association was not found. And Rosenblatt *et al.* examined the association across four categories of increasing lifetime applications.<sup>98</sup> There was no statistically significant elevated risk for women who reported between 4,800 and 9,999 lifetime applications (RR 0.78, 95% confidence interval 0.41-1.48 for invasive tumors; RR 0.87, 95% confidence interval 0.5-1.53 for all tumors) and women with more than 10,000 lifetime applications (RR 0.84, 95% confidence interval 0.44-1.59 for invasive tumors; RR 0.87, 95% confidence interval 0.48-1.57 for all tumors).

Plaintiffs have also failed to put forward any accepted biological mechanism by which genital talc use could cause EOC. As Dr. Clarke-Pearson puts it, “ascension of talcum powder and its constituents through the genital tract is the most important route of exposure.”<sup>99</sup> But, as discussed in detail above, the studies examining this issue do not support plaintiffs’ migration theory of biologic plausibility. Plaintiffs’ experts claim to have reviewed these studies, but their explanations are unconvincing. For example, Dr. Blair Smith states that she reviewed the “articles that dispute talcum powder’s ability to reach the tubes and ovaries” and “rejected these

---

<sup>94</sup> Wolf Report at 7; Clarke-Pearson Report at 6.

<sup>95</sup> Schildkraut *et al.* Association between body powder use and ovarian cancer: the African American cancer epidemiology study. *Cancer Epidemiol, Biomarkers Prev* 2016; 25(10): 1411-1416.

<sup>96</sup> Cook *et al.* Perineal powder exposure and the risk of ovarian cancer. *Am. J. Epidemiology* 1997; 145:459, 463.

<sup>97</sup> Mills *et al.* Perineal talc exposure and epithelial ovarian cancer risk in the Central Valley of California. *Int’l J. Cancer* 2004; 112: 458-464.

<sup>98</sup> Rosenblatt *et al.* Genital powder exposure and the risk of epithelial ovarian cancer. *Cancer Causes Control* 2011; 11: 737-742.

<sup>99</sup> Clarke-Pearson Report at 8; Wolf Report at 15; Blair Smith Report at 20.

claims.” Similarly, Dr. Wolf claims to have “considered the limited evidence to the contrary and find it non-persuasive,”<sup>100</sup> and Dr. Clarke-Pearson states that he “reviewed the small body of literature suggesting that migration of particles does not occur and do[es] not think these studies are compelling.”<sup>101</sup> Such selective review of studies is clearly conclusion-driven.

The studies that plaintiffs’ experts did address also do not confirm their hypothesis. For example, reliance on studies showing migration of “motile” sperm and bacteria<sup>102</sup> is misplaced because the movement of these substances is obviously and starkly different from any purported mobility of talc. Additionally, although plaintiffs point to studies that identified talc particles in ovarian tissue, this fact cannot be evidence of talc migration because studies have found talc particles in the ovaries of women with and without perineal talc use. For example, the Heller (1996) study cited by Drs. Clarke-Pearson and Wolf<sup>103</sup> found that “talc particles were observed to a similar extent with both exposed and unexposed subjects.”<sup>104</sup> Notably, Dr. Clarke-Pearson confirmed at his deposition that none of the articles he cited actually looked at whether talc can migrate from the perineal application through the fallopian tubes to the ovaries.<sup>105</sup>

Additionally, as discussed above, although the ascension of talc through the fallopian tubes to the ovaries is central to the hypothesis that genital talc increases the risk of EOC, studies have found no decreased risk of serous ovarian cancer in women who underwent tubal ligation.<sup>106</sup> Drs. Clarke-Pearson, Wolf and Blair Smith conclude that tubal ligation and hysterectomy are protective factors, but they fail to address this point.<sup>107</sup>

Several of plaintiffs’ experts point to work done by Dr. Ghassan Saed – who is himself a plaintiffs’ expert – in support of their contention that experimentation confirms that talc use causes ovarian cancer. For example, Dr. Clarke-Pearson (who did not realize Dr. Saed was a plaintiffs’ expert paid to conduct his research<sup>108</sup>) cites Dr. Saed to support his contention that “[l]aboratory research (in vitro) present[s] evidence to support the biologic, genetic and epigenetic consequence to ovarian epithelium when exposed to talcum powder.”<sup>109</sup> Plaintiffs’ experts overstate the impact of Dr. Saed’s results. For example, he reports an increase in CA-125 expression, but CA-125 elevation alone is not evidence of ovarian cancer, as it is a well-known marker of inflammation, and Dr. Saed’s *in vitro* results have not been replicated in any *in vivo*

---

<sup>100</sup> Wolf Report at 11.

<sup>101</sup> Clarke-Pearson Report at 8.

<sup>102</sup> Clarke-Pearson Report at 7; Wolf Report at 10.

<sup>103</sup> Clarke-Pearson Report at 8; Wolf Report at 11.

<sup>104</sup> Heller DS, *et al.* Asbestos exposure and ovarian fiber burden. *Am J Ind Med* 1996; 29: 435-439.

<sup>105</sup> February 4, 2019 Deposition of Daniel L. Clarke-Pearson, M.D., at 200:20-25.

<sup>106</sup> Gertig DM, Hunter DJ, Cramer DW, *et al.* Prospective study of talc use and ovarian cancer. *J Natl Cancer Inst* 2000; 92: 249-252; Terry KL, *et al.* Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. *Cancer Prev Res* 2013; 6(8): 811-821.

<sup>107</sup> Blair Smith Report at 3; Wolf Report at 4; Clarke-Pearson Report at 5.

<sup>108</sup> February 4, 2019 Deposition of Daniel L. Clarke-Pearson, M.D., at 253:1-2.

<sup>109</sup> Clarke-Pearson Report at 9.

studies. I also understand that there a number of irregularities in Dr. Saed's work and his lab notebooks. In addition, an inflammatory response is not the equivalent of malignant transformation. As described above, talc is used in pleurodesis, which causes inflammation, but has not been identified as increasing cancer risk. In fact, recent studies suggest an improved survival rate in patients with pleural mesothelioma treated with talc pleurodesis.<sup>110</sup> Moreover, the expected inflammatory reaction (foreign body granulomas) has not been identified on tissue of women with ovarian cancer even in the presence of talc.<sup>111</sup>

Another Bradford Hill factor is analogy – i.e., whether there are similar associations that have been confirmed as causal. Dr. Wolf points to “other diseases caused by various and specific carcinogens”<sup>112</sup> and provides the following examples: “smoking causes lung cancer, asbestos causes mesothelioma and ovarian cancer, sun exposure causes skin cancer, and HPV causes cervical cancer.”<sup>113</sup> She goes on to incorrectly assert that “all of these cancers are the result of an inflammatory process initiated by a foreign agent.”<sup>114</sup> HPV does not cause cervical cancer via inflammation, but rather by molecular interactions between viral and host gene products. In fact, in the case of HPV, inflammation actually decreases the risk of persistent infection and progression of precursor lesions toward cancer.<sup>115</sup> More importantly, just because some environmental factors cause some types of cancer, that does not mean they are analogous to the proposed association between talc and ovarian cancer.

## **Conclusion**

As a gynecologic oncologist, I have focused my entire career on the study and treatment of ovarian cancer and other gynecological diseases. I believe that it is essential that scientific resources are dedicated to understanding ovarian cancer and investigating potential causes of the disease. But it is just as important that those resources are not wasted on efforts to establish an association between ovarian cancer and talc exposure (or any other factor) based on a hypothesis that is being pursued in connection with product liability litigation. Indeed, such efforts distract the medical and scientific communities' attention from legitimate science-based areas of inquiry and research.

This diversion of the scientific community's attention is evident in the work of Penninkilampi and Eslik,<sup>116</sup> discussed above, who devoted significant time and resources to a meta-analysis evaluating ovarian cancer and genital talc use that was admittedly based, at least in part, on

---

<sup>110</sup> Korsic M, *et al.* Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study. *Wien Klin Wochenschr (Central Eur J Med)* 2015; 127: 963-969.

<sup>111</sup> Heller DS, *et al.* Asbestos exposure and ovarian fiber burden. *Am J Ind Med* 1996; 29: 435-439.

<sup>112</sup> Wolf Report at 16.

<sup>113</sup> Wolf Report at 16.

<sup>114</sup> Wolf Report at 16.

<sup>115</sup> Kovacic M, *et al.* Epidemiologic analysis of histologic cervical inflammation: relationship to human papillomavirus. *Human Pathology* 2008; 39: 1088-1095.

<sup>116</sup> Penninkilampi, R and Eslik, GD. Perineal talc use and ovarian cancer: a systematic review and meta-analysis. *Epidemiology* 2018; 29: 41-49. <https://doi.org/10.1097/EDE.0000000000000745>.

media and other attention spurred by this litigation – and then pointedly excluded qualifying studies from their analysis that failed to show such a link.

The focus on talc as a potential cause of ovarian cancer is misguided and extremely troubling given the low strength of association between genital talc exposure and ovarian cancer that has been observed in the few studies that have identified any association at all. According to several of plaintiffs' experts, this low strength of association should be excused because ovarian cancer is "a fatal disease" and therefore any risk, however slight, is significant.<sup>117</sup> In short, plaintiffs' experts' position seems to be that ovarian cancer is a public health crisis and therefore the scientific community should put aside recognized standards for determining causality in an effort to connect the disease to any possible cause. This is backwards. The gravity of ovarian cancer requires independent, patient-focused research and not litigation-driven research or multiple meta-analyses all examining the same flawed studies.

Ovarian cancer is the deadliest of all gynecologic cancers. There is no effective screen for early detection and our ability to reverse the chemo-resistance that ultimately leads to the death of our patients has been disappointing. Surely if convincing data existed regarding an easily eradicated cause of the disease, the gynecologic oncology community would aggressively pursue a public health agenda to do just that. No such effort exists for a reason. As a gynecologic oncologist, I urge my patients and my primary care colleagues to be aware of the symptoms of ovarian cancer, I educate my patients on the importance of genetic counseling and testing, and I continue to research innovations that could lead to earlier detection. I do not recommend against genital talc use because there is insufficient data to support such a recommendation.

---

<sup>117</sup> Blair Smith Report at 19; January 9, 2019 Deposition of Ellen Blair Smith, M.D., at 176; Clarke-Pearson Report at 8 (noting that a 1.3 odds ratio is "critically important" "considering the severity and frequency of ovarian cancer and the preventable nature of talcum powder usage").

### Materials Reviewed and Considered

1. ACOG, Frequently Asked Questions: Gynecologic Problems: Ovarian Cancer  
<https://www.acog.org/Patients/FAQs/Ovarian-Cancer#risk>.
2. Acheson, ED. *et al*, Mortality of two groups of women who manufactured gas masks from chrysotile and crocidolite asbestos: a 40-year follow-up. *Br J Ind Med* 1982; 39(4):344-348.
3. Baandrup L., *et al*. Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: a systematic review and meta-analysis of observational studies. *Obstet Gynecol Scand* 2013; 92:245-255.
4. Berge, W. *et al*. Genital use of talc and risk of ovarian cancer: a meta-analysis. *Eur J Cancer Prev* 2018; 27:248-257.
5. Bonovas S, *et al.*, Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis, *Br J Clin Pharmacol* 2005; 60(2):194-203.
6. Booth M, *et al.*, Risk factors for ovarian cancer: a case-control study. *Br J Cancer* 1989; 60: 592-8.
7. Bosch FX, *et al*. The causal relation between human papillomavirus and cervical cancer. *J Clin Pathol* 2002; 55(4): 244–265.
8. Carmago MC, *et al*. Occupational exposure to asbestos and ovarian cancer – meta-analysis. *Environ Health Perspectives* 2011; 119: 1211-1217.
9. Carr CJ, Talc: consumer uses and health perspectives. *Reg Toxicol Pharmacol* 1995; 21: 211-215.
10. Center for Evidence-Based Management, What are the levels of evidence?.  
<https://www.cebma.org/faq/what-are-the-levels-of-evidence/> [last visited January 2019].
11. CDC, What are the risk factors for ovarian cancer?  
[https://www.cdc.gov/cancer/ovarian/basic\\_info/risk\\_factors.htm](https://www.cdc.gov/cancer/ovarian/basic_info/risk_factors.htm).
12. Chang S and HA Risch. Perineal talc exposure and risk of ovarian carcinoma. *Cancer* 1997; 79:2396-2401.
13. Chen Y, *et al*. Risk factors for epithelial ovarian cancer in Beijing, China. *Intl J Epidemiol* 1992; 21(1): 23-29.
14. Cook LS, *et al*. Perineal powder exposure and the risk of ovarian cancer. *Am J Epidemiol* 1997; 145(5): 459-65.
15. Coughlin S. Recall Bias in Epidemiological Studies. *J Clin Epidemiol* 1990; 43(1): 87-91.
16. Cramer DW, *et al*. Ovarian cancer and talc: a case-control study. *Cancer* 1982; 50(2): 372–6.

17. Cramer DW., *et al.* Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer. *Annals of Epidemiol* 1995; 5(4), 310-314.
18. Cramer DW., *et al.* Over-the-counter analgesics and risk of ovarian cancer. *The Lancet* 1998; 351(9096), 104-107.
19. Cramer DW, *et al.* Genital talc exposure and risk of ovarian cancer. *Int J Cancer* 1999; 81:351-56.
20. Cramer DW, *et al.* Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. *Cancer Epidemiol Biomarkers Prev* 2005; 14(5): 1125-31.
21. Cramer DW, *et al.* Presence of talc in pelvic lymph nodes of a woman with ovarian cancer and long-term genital exposure to cosmetic talc. *Obst Gyn* 2007; 110(2): 498-501.
22. Cramer DW, *et al.* The association between talc use and ovarian cancer: a retrospective case-control study in two US states. *Epidemiology* 2016; 27(3):334-46.
23. Crawford, *et al.* Perineal powder use and risk of endometrial cancer in postmenopausal women. *Cancer Causes Control* 2012; 23:1673-80.
24. Cubillos-Ruiz JR, *et al.* Tumorigenic and Immunosuppressive effects on endoplasmic reticulum stress in cancer. *Cell* 2017; 168: 692–706.
25. Davies HE, Mishra EK, Kahan BC, *et al.* Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. *JAMA* 2012; 307(22):2383–2389.
26. Domcheck SM., *et al.* Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *JAMA* 2010; 304(9):967-75.
27. Egli GE and Newton M., The transport of carbon particles in the human female reproductive tract. *Fertility and Sterility* 1961; 12(1): 151-155.
28. Eng K., *et al.* Paternal lineage early onset hereditary ovarian cancers: a familial ovarian cancer registry study. *PLOS Genetics* 2018; 14 (2): e1007194.
29. Faber M, *et al.* Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. *Cancer Causes Control*. 2013; 24(5):1-26.
30. Fairfield KM, *et al.* Aspirin, other NSAID, and ovarian cancer risk (United States). *Cancer Causes and Control* 2002; 13:535-42.
31. Fathalla MF, Incessant ovulation – a factor in ovarian neoplasia. *Lancet* 1971; 2(7716), 163.
32. Fiume MM, *et al.* Safety assessment of talc as used in cosmetics. *Int J Toxicol* 2015; 34 (1 supp): 66S-129S.

33. Food and Drug Administration, Statement on Talc (2015).
34. Food and Drug Administration. Talc. U.S. Department of Health and Human Services, 2014. Available online: <http://www.fda.gov/Cosmetics/ProductsIngredients/Ingredients/ucm293184.html>.
35. Food and Drug Administration. Letter from Musser SM to Epstein SS re: Docket Numbers 94P-0420 and FDA 2008-P-0309-0001/CP, Apr. 1, 2014.
36. Fletcher NM, *et al.* Talcum powder enhances oxidative stress in ovarian cancer cells, *Reproductive Sciences* 25, 214A-215A.
37. Friedlander ML, Prognostic factors in ovarian cancer. *Semin Oncol* 1998; 25(3): 305-314.
38. Garg PP, *et al.*: Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. *Obstet Gynecol* 1998; 92 (3): 472-479.
39. Gates, *et al.* Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev* 2008; 17(9): 2436-44.
40. Gates, *et al.* Risk Factors for Epithelial Ovarian Cancer by Histologic Subtype. *Am J Epidemiol* 2010; 171: 45-53. <http://doi.org/10.1093/aje/kwp314>.
41. Germani D. *et al.* Cohort mortality study of women compensated for asbestosis in Italy. *Am J Indus Med* 1999;36(1):129-134.
42. Gertig DM, Hunter DJ, Cramer DW, *et al.* Prospective study of talc use and ovarian cancer. *J Natl Cancer Inst* 2000; 92: 249-52.
43. Godard B, *et al.* Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. *Am J Obstet Gynecol* 1998; 179(2): 403-410.
44. Gonzalez N., *et al.* Douching, talc use, and risk of ovarian cancer. *Epidemiol* 2016; 27(6): 797-802.
45. Green A., *et al.* Tubal sterilization, hysterectomy and decreased risk of ovarian cancer. *Intl J Cancer* 1997; 71(6): 948-51.
46. Gross AJ, *et al.* A meta-analytical approach examining the potential relationship between talc. *J Exp Anal Environ Epidemiol* 1995; 5(2): 181-195.
47. Györik, *et al.* Long-term follow-up of thoracoscopic talc pleurodesis for primary spontaneous pneumothorax. *Eur. Resp J* 2007; 29(4):757-60.
48. Harlow BL, *et al.* A case-control study of borderline ovarian tumors: the influence of perineal exposure to talc. *Am J Epidemiol* 1989; 130(2):390-94.
49. Harlow BL, *et al.* Perineal exposure to talc and ovarian cancer risk. *Obstet Gynecol* 1992; 80:19-26.

50. Hartge P., *et al.* Talc and ovarian cancer. *JAMA* 1984; 250:1844.
51. Hill A. Environment and disease: association or causation? *Proc Royal Soc Med* 1965; 58:295-300.
52. Houghton SC, *et al.* Perineal powder use and risk of ovarian cancer. *J Natl Cancer Inst* 2014; 106(9): dju208.
53. Heller DS, *et al.* Asbestos exposure and ovarian fiber burden. *Am J Ind Med* 1996; 29:435-439.
54. Heller DS, *et al.* The relationship between perineal cosmetic talc usage and ovarian talc particle burden. *Am J Obstet Gynecol* 1996; 174:1507-1510.
55. Henderson WJ, *et al.* Talc and carcinoma of the ovary and cervix. *Tenovus Inst. Cancer Research* 1971; 266-272.
56. Henderson WJ, *et al.* The demonstration of the migration of talc from the vagina and posterior uterus to the ovary in the rat. *Environ Research* 1986; 40: 247-50.
57. Huncharek, *et al.* Perineal applications of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from 16 observational studies. *Intl J Cancer Research and Treatment* 2003; 23:1955-1960.
58. Huncharek, *et al.* Use of Cosmetic talc on contraceptive diaphragms and risk of ovarian cancer: a meta-analysis of nine observational studies. *Eur J Cancer Prev* 2007; 16:422-29.
59. IARC Monograph. Carbon black, titanium dioxide, and talc. 2010; 93:1-413, pg. 305.
60. IARC Monograph. Arsenic, Metals, Fibres, and Dusts, Volume 100C, A Review of Human Carcinogens. 2012; 100(C):11-465.
61. Jordan SJ, *et al.* Risk factors for benign serous and mucinous epithelial ovarian tumors. *Obstet Gynecol* 2007; 109:647-54.
62. Jordan SJ., *et al.* Breastfeeding and risk of epithelial ovarian cancer. *Cancer Causes & Control* 2010; 21(1): 109-116.
63. Karageorgi, Gates, *et al.* Perineal use of talcum powder and endometrial cancer risk. *Cancer Epidemiol, Biomarkers Prev* 2010; 19:1269-1275.
64. Korsic M, *et al.* Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study. *Wien Klin Wochenschr (Central Eur J Med)* 2015; 127:963-969.
65. Kotsopoulos, *et al.* Ovarian cancer risk factors by tumor dominance, a surrogate for cell or origin. *Int J Cancer* 2013; 133:730-40.

66. Kovacic M, et al. Epidemiologic analysis of histologic cervical inflammation: relationship to human papillomavirus. *Human Pathology* 2008; 39:1088-1095.
67. Kuchenbaecker KB, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *JAMA* 2017; 317(23):2402-2416.
68. Kurta ML, et al. Use of fertility drugs and risk of ovarian cancer: results from a US-based case-control study. *Cancer Epidemiol Prev Biomarkers* 2012; 21(8): 1282-92.
69. Lacey JV Jr, Mink PJ, Lubin JH, et al.: Menopausal hormone replacement therapy and risk of ovarian cancer. *JAMA* 288 (3): 334-41, 2002
70. Langseth H., et al., Asbestos fibers in ovarian tissue from Norwegian pulp and paper workers. *Intl J Gynecol Cancer* 2007; 17(1): 44-49.
71. Langseth H., et al. Perineal use of talc and risk of ovarian cancer. *J Epidemiol Comm Health* 2008; 62(4): 358-60.
72. Lehtinen M, et al. Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the nordic countries. *Am J Epidemiol* 2002; 156(8): 687–692.
73. Lim, et al. Morphological and immunohistochemical reevaluation of tumors initially diagnosed as ovarian endometrioid carcinoma with emphasis on high-grade tumors. *Am J Surg Pathol* 2016; 40: 302–312.
74. Lo-Ciganic WH, et al. Aspirin, Non-aspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. *Epidemiology* 2012; 23(2): 311.
75. Magnani C. et al. Cancer risk after cessation of asbestos exposure: a cohort study of Italian asbestos cement workers. *Occupational and environmental medicine.* 2008;65(3):164-170.
76. Merritt MA, et al. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. *Intl J Cancer* 2008; 122(1): 170-176.
77. Mills PK, et al.: Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. *Cancer Detect Prev* 2005; 29 (2): 124-32
78. Mills PK, et al. Perineal talc exposure and epithelial ovarian cancer risk in the central valley of California. *Int J Cancer* 2004; 112:458-64.
79. Moorman PG, et al. Ovarian cancer risk factors in African-American and white women. *Am J Epidemiol* 2009; 170(5): 598-606.
80. Mullany, LK, et al. Wild-type tumor repressor protein 53 (TRP53) promotes ovarian cancer cell survival. *Endocrinology* 2012; 153(4): 1638-48.
81. Muscat JE and Huncharek MS. Perineal talc use and ovarian cancer: a critical review. *Eur J Cancer Prev* 2008; 17:139-46.

82. Nahmias AJ, Josey WE, Naib ZM, *et al.* Antibodies to herpesvirus hominis types 1 and 2 in humans. II. Women with cervical cancer. *Am J Epidemiol* 1970; 91:547–52.
83. Narod S, *et al.* Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary ovarian cancer clinical study group. *N Engl J Med* 1998; 339(7): 424-428.
84. Nasreen N, *et al.* Talc induces apoptosis in human malignant mesothelioma cells in vitro. *Am J Respir Crit Care Med* 2000; 161:595-600.
85. National Cancer Institute, Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention (PDQ), Health Professional Version.  
[https://www.cancer.gov/types/ovarian/hp/ovarian-prevention-pdq#cit/section\\_1.11](https://www.cancer.gov/types/ovarian/hp/ovarian-prevention-pdq#cit/section_1.11).
86. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: breast and ovarian. Version 2.217. December 7, 2017.
87. National Institute of Health, SEER Cancer Stat Facts: Ovarian Cancer. National Cancer Institute. Bethesda, MD, <https://seer.cancer.gov/statfacts/html/ovary.html> (last visited January 2019).
88. Neill, *et al.* Use of talcum powder and endometrial cancer risk, *Cancer Causes Control* 2012; 23:513-519.
89. Ness R., Does talc exposure cause ovarian cancer? IGCS-0015 *Int J Gynecol Cancer* 2015; 25(Suppl 1): 51.
90. Ness RB, *et al.* Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. *Epidemiology* 2000; 11:111-117.
91. Ni X, *et al.*, Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer *Br J Clin Pharmacol* 2012; 75(1): 26-35.
92. Ovarian Cancer: Results from the Danish MALOVA Study. *Cancer Epidemiol Biomarkers Prev* 2007; 16: 1160-1166.
93. Ovarian Cancer Research Alliance *Risk Factors* <https://ocrahope.org/patients/about-ovarian-cancer/risk-factors/>.
94. Penninkilampi, Ross and Guy D. Eslik. Perineal talc use and ovarian cancer: a systematic review and meta-analysis. *Epidemiology* 2018; 29: 41-49.  
<https://doi.org/10.1097/EDE.0000000000000745>.
95. Peres LC., *et al.* Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. *Int J Epidemiol* 2017; 0: 1-13.
96. Perren, TJ. Mucinous epithelial ovarian carcinoma. *Annals of Oncol* 2016; 27:i53-i57.

97. Pike MC, *et al.* Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. *Fertility and Sterility* 2004; 83(1): 186-195.
98. Purdie D., *et al.* Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. *Int J Cancer* 1995; 62: 678-684.
- Rawls WE, Adam E, Melnick JL. An analysis of seroepidemiological studies of herpes virus type 2 and carcinoma of the cervix. *Cancer Res* 1972; 33:1479-82.
99. Rasmussen, CB, *et al.* Is pelvic inflammatory disease a risk factor for ovarian cancer? *Cancer Epidemiol Biomarkers Prev* 2017; 26(1): 104-109.
100. Research Committee of the British Thoracic Association and the Medical Research Council Pneumoconiosis Unit; Research Counsel Pneumoconiosis. A survey of the long-term effects of talc and kaolin pleurodesis. *Br J Dis Chest* 1979; 73:285-88.
101. Riman T, *et al.* Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. *Gynecol Oncology* 2001; 83:575-585.
102. Reid et al., *Cancer Incidence Among Women and Girls Environmentally and Occupationally Exposed to Blue Asbestos at Wittenoom, Western Australia*, 122 Int'l J. Cancer 2337 (2008).
103. Reid A, *et al.* Does exposure to asbestos cause ovarian cancer? A systematic literature review and meta-analysis. *Cancer Epidemiol, Biomarkers Prev* 2011; 20(7): 1287-1295.
104. Rosenblatt KA., *et al.* Mineral fiber exposure and the development of ovarian cancer. *Gyn Onc* 1992; 45:20-25.
105. Rosenblatt KA, *et al.* Characteristics of women who use perineal powders. *Obstet Gynecol* 1998; 92(5): 753-756.
106. Rosenblatt KA, *et al.* Genital powder exposure and the risk of epithelial ovarian cancer. *Cancer Causes & Control* 2011; 22(5): 737-42.
107. Schildkraut *et al.*, Association between body powder use and ovarian cancer: the African American cancer epidemiology study. *Cancer Epidemiol Biomarkers Prev* 2016; 25(10):1411-1416.
108. Sethna K, *et al.* Cytoreductive surgery and intraperitoneal chemotherapy for advanced epithelial ovarian Ccancer. Chapter 10 in *Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond*. 2018, pg. 10.
109. Shushan A, *et al.* Human menopausal gonadotropin and the risk of epithelial ovarian cancer. *Fertility and Sterility* 1996; 65(1): 13-18.
110. Sieh W., *et al.* Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. *Intl J Epidemiol* 2013; 42(2): 579-89.

111. SGO, Ovarian cancer: risk factors. <https://www.sgo.org/patients-caregivers-survivors/caregivers/ovarian-cancer-risk-factors/>.
112. Steiling W, *et al.* Principles for the safety evaluation of cosmetic powders. *Toxicology Letters* 2018; <https://doi.org/10.1016/j.toxlet.2018.08.011>.
113. Soegaard M, *et al.* Different Risk Factor Profiles for Mucinous and Nonmucinous Ovarian Cancer: Results from the Danish MALOVA Study. *Cancer Epidemiol Biomarkers Prev* 2007; 16: 1160-1166.
114. Song M, *et al.* IRE1 $\alpha$ -XBP1 Controls T cell function in ovarian cancer by regulating mitochondrial activity. *Nature* 2018; 562: 423–428.
115. Soyama H, *et al.* Pathological study using 2014 who criteria reveals poor prognosis of grade 3 ovarian endometrioid carcinomas, *In Vivo* 2018; 32: 597–602.
116. The periodic health examination. Canadian Task Force on the Periodic Health Examination. *Can Med Assoc J.* 1979; 121:1193–1254.
117. Terry KL, *et al.* Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. *Cancer Prev Res* 2013:DOI:10.1158/1940-6207.CAPR-13-0037.
118. Torre LA, *et al.* Ovarian Cancer Statistics, 2018. *CA Cancer J. Clin.* 2018; 68: 284-296.
119. Toss A, *et al.* Hereditary ovarian cancer: not only BRCA 1 and 2 genes. *Biomed Res Int* 2015: 341723.
120. Trabert et al., Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium, *J. Nat'l Cancer Inst.* (2019) 111(2):137-145, 139-42.
121. Trabert B, *et al.*, Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the ovarian cancer association consortium. *J Natl Cancer Inst* 2014; 106(2): 1-11.
122. Tzonou A., *et al.* Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer. *Intl J Cancer* 1993; 55:408-10.
123. Venter M., Migration of particulate radioactive tracer from the vagina to the peritoneal cavity and ovaries. *S African Med J* 1979; 55(23): 917-19.
124. Viksum K, *et al.* Long term sequelae after talc pleurodesis for spontaneous pneumothorax. *Pneumologie* 1989; 43:105-106.
125. Vonka V, Kanka J, Jelinek I, *et al.* Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. *Int J Cancer* 1984;33:61–8.
126. Wehner AP, Weller RE, Lepel EA. *Food Chem Toxicol.* 1986; 24(4):329-38.

127. Wenlong Q, *et al.* Dietary fat intake and ovarian cancer risk: a meta-analysis of epidemiological studies. *Oncotarget* 2016; 7(24): 37390-37406.
128. Whittemore AS, *et al.* Personal and environmental characteristics related to epithelial ovarian cancer. Exposures to talcum powder, tobacco, alcohol, and coffee. *Am J Epidemiol* 1988; 128:1228-1240.
129. Wong C, *et al.* Perineal talc exposure and subsequent epithelial ovarian cancer: a case-control study. *Obstet Gynecol* 1999; 93: 372-76.
130. Wu AH, *et al.* Markers of inflammation and risk of ovarian cancer in Los Angeles County. *Intl J Cancer* 2009; 124:1409-1415.
131. Wu AH, *et al.* African-Americans and Hispanics remain at lower risk of ovarian cancer than non-Hispanic Whites after considering non-genetic risk factors and oophorectomy rates. *Cancer Epidemiol Biomarkers Prev* 2015; 24(7): 1094-1100.
132. Zhou Z, *et al.* Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis. *Cancer Causes Control* 2017 May; 28(5) 415-428. Doi:10.1007/s10552-017-0873-3.

Other materials reviewed:

- Expert Report of Daniel L. Clarke-Pearson, M.D. (filed Nov. 16, 2018).
- Expert Report of Ellen Blair Smith, M.D. (filed Nov. 16, 2018).
- Expert Report of Judith Wolf, M.D. (filed Nov. 16, 2018).
- January 7, 2019 Deposition transcript of Judith K. Wolf, M.D. and exhibits.
- January 9, 2019 Deposition transcript of Ellen Blair Smith, M.D. and exhibits.
- January 23, 2019 Deposition transcript of Ghassan Saed, Ph.D. and exhibits.
- February 4, 2019 Deposition transcript of Daniel L. Clarke-Pearson, M.D. and exhibits.
- February 14, 2019 Deposition transcript of Ghassan Saed, Ph.D. and exhibits.

Table 1

Study Type	Year	Author	Journal	Title	Analysis	Odds Ratio / Relative Risk	95% CI
Case-Control	1982	Cramer	Cancer	Ovarian cancer and talc: A case-control study	Any perineal exposure (via dusting and/or napkins)	1.92	(1.27, 2.89)
Case-Control	1983	Hartge	JAMA	Talc and ovarian cancer	Any talc use; Any genital talc use (on genitals, napkins, or underwear)	0.7 (Any talc); 2.5 (Genital)	(0.40, 1.10) Any talc; (0.70, 10.0) Genital
Case-Control	1988	Whittemore	Am J Epidemiol	Personal and environmental characteristics related to epithelial ovarian cancer. Exposures to talcum powder, tobacco, alcohol, and coffee	"Perineum only" talc use	1.45	(0.81, 2.60)
Case-Control	1989	Booth	BR Cancer	Risk factors for ovarian cancer: A case-control study	Daily talc use in genital area	1.3	(0.80, 1.9)
Case-Control	1989	Harlow	Am J Epidemiol	A case-control study of borderline ovarian tumors: The influence of perineal exposure to talc	Any perineal exposure to powder	1.1	(0.70, 2.1)
Case-Control	1992	Chen	Int J Epidemiol	Risk factors for epithelial ovarian cancer in Beijing, China	≥3 months of application of talc-containing dusting powder to the lower abdomen and perineum	3.9	(0.9, 10.6)
Case-Control	1992	Harlow	Obstet Gynecol	Perineal exposure to talc and ovarian cancer risk	Any genital talc application	1.5	(1.0, 2.1)
Case-Control	1992	Rosenblatt	Gynecol Oncol	Mineral fiber exposure and the development of ovarian cancer	Genital bath talc use (Yes/No)	1.7	(0.70, 3.9)
Case-Control	1993	Tzonou	Int J Cancer	Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer	"Talc application in the perineum"	1.05	(0.28, 3.98)
Case Control	1995	Cramer	AEP	Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer	Talc use (Yes/No)	1.6	(1.2, 2.1)
Case-Control	1995	Purdie	Int J Cancer	Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study	Use of talc around abdomen/perineum	1.27	(1.04, 1.54)
Case-Control	1997	Chang	Cancer	Perineal talc exposure and risk of ovarian carcinoma	"Any regular talc exposure"	1.42	(1.08, 1.86)
Case-Control	1997	Cook	Am J Epidemiol	Perineal powder exposure and the risk of ovarian cancer	Any use of talcum powder	1.6	(0.9, 2.8)
Case-Control	1997	Green	In J Cancer	Tubal sterilization, hysterectomy and decreased risk of ovarian cancer.	"Use of talc in the perineal region" among women with surgical tubal occlusion; Among women without surgical sterilization	1.3 (Without)	(1.1, 1.6) With surgery; (1.0, 1.7) Without
Case-Control	1998	Godard	Am J Obstet Gynecol	Risk factors for familial and sporadic ovarian cancer among French Canadians: A case-control study	Ever/never "Use of talc on perineum"	2.49	(0.94, 6.58)
Case-Control	1999	Cramer	International J of Cancer	Genital talc exposure and risk of ovarian cancer	Any personal genital powder exposure	1.6	(1.18, 2.15)
Case-Control	1999	Wong	Obstet Gynecol	Perineal talc exposure and subsequent epithelial ovarian cancer: A case-control study	Talc use on genital/thigh area and on sanitary napkins	1.1	(0.7, 1.7)
Case-Control	2000	Ness	Epidemiol	Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer	Genital/rectal use (at least once per month for six or more months)	1.5	(1.1, 2.0)
Case-Control	2004	Mills	Am J Epidemiol	Perineal talc exposure and epithelial ovarian cancer risk in the Central Valley of California	Ever/never genital talc use	1.37	(1.02, 1.85)
Case-Control	2004	Pike	Fertil Steril	Hormonal factors and the risk of invasive ovarian cancer: A population based case control study	"Use of genital area talc" (Yes/No)	1.6	(1.18, 2.18)
Case-Control	2005	Cramer	Cancer Epid Bio Prev	Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer	"Genital use" of talc	1.16	(0.9, 1.49)
Case-Control	2007	Jordan	Obstet Gynecol	Risk factors for benign serous and mucinous epithelial ovarian tumors	"Use of talc in the Perineal Region" (Yes/No)	1.1	(0.84, 1.45)
Case-Control	2008	Gates	Cancer Epid Bio Prev	Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer	"Regular genital talc use" (once per week or more)	1.36	(1.14, 1.63)
Case-Control	2008	Goodman	Endcor Relat Cancer	Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk	Genital powder use (*As reported in Terry 2013 pooled analysis, ref. 25)	0.99	(0.70, 1.41)
Case-Control	2008	Merritt	Int J Cancer	Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer	Ever/never use of talc in perineal region	1.17	(1.01, 1.36)
Case-Control	2009	Moorman	Am J Epidemiol	Ovarian cancer risk factors in African-American and white women	"Talc use" (Yes/No)	1.04 (White); 1.19 (AA)	(0.82, 1.33) White; (0.68, 2.09) AA
Case-Control	2009	Wu	Int J Cancer	Markers of inflammation and risk of ovarian cancer in Los Angeles County	"Ever" use of talc ("Ever" if used at least once per month for 6 months or more)	1.48	(1.15, 1.91)
Case-Control	2011	Rosenblatt	Gynecol Oncol	Genital powder exposure and the risk of epithelial ovarian cancer	Regular direct perineal powder application after bathing	1.27	(0.97, 1.66)
Case-Control	2012	Kurta	Cancer Epid Bio Prev	Use of fertility drugs and risk of ovarian cancer: Results from a U.S.-based case-control study	"Ever" use of talc in perineal region	1.4	(1.16, 1.69)
Case-Control	2012	Lo-Cignaic	Epidemiol	Aspirin, non-aspirin non-steroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer	Any genital talc use at least once per month for six months or more (*As reported in Terry 2013 pooled analysis, ref. 26)	1.34	(1.07, 1.66)
Case-Control	2015	Wu	Cancer Epid Bio Prev	African Americans and Hispanics remain at lower risk of ovarian cancer than non-Hispanic whites after considering nongenetic risk factors and oophorectomy rates	≥ 1 Year of genital talc use	1.46	(1.27, 1.69)
Case-Control	2016	Cramer	Epidemiology	The association between talc use and ovarian cancer - A retrospective case-control study in two US states	Any personal genital talc use	1.33	(1.16, 1.52)
Case-Control	2016	Schildkraut	Cancer Epid Bio Prev	Association between body powder use and ovarian cancer: The African American Cancer epidemiology study	Any genital powder use	1.44	(1.11, 1.86)

# EXHIBIT A

**CURRICULUM VITAE**

<b>NAME</b>	Kevin Holcomb, M.D., FACOG
<b>TITLE AND AFFILIATION</b>	Associate Professor of Clinical Obstetrics and Gynecology Weill Medical College of Cornell University  Vice-Chairman of Gynecology Director of Gynecologic Oncology Director of Minimally Invasive Surgery Department of Obstetrics and Gynecology Weill-Cornell Medicine  Attending Physician Division of Gynecologic Oncology New York-Presbyterian Hospital
<b>BIRTHDATE</b>	April 13, 1967
<b>PLACE OF BIRTH</b>	Brooklyn, NY
<b>BUSINESS ADDRESS</b>	525 East 68 <sup>th</sup> Street, Suite J130 New York, NY 10021
<b>TELEPHONE</b>	(212) 746-7553
<b>EDUCATION</b>	New York Medical College Valhalla, NY 7/88- 6/92 M.D.  Cornell University Ithaca, NY College Scholar Program 9/84-6/88 B.A.
<b>POSTGRADUATE TRAINING</b>	
Residency	Obstetrics and Gynecology The New York Hospital Cornell Medical Center 7/92-7/96
Fellowship	Gynecologic Oncology State University of New York Health Science Center at Brooklyn Kings County Hospital Center 7/96-6/99

Kevin Holcomb, M.D.

<b>WORK EXPERIENCE</b>	Assistant Clinical Professor Columbia University College of Physicians and Surgeons New York, NY	4/2001-2/2006
	Director of Gynecologic Oncology Beth Israel Medical Center New York, NY	1/2001-2/2006
	Attending Physician Division of Gynecologic Oncology St. Luke's-Roosevelt Hospital New York, NY	1/2001-2/2006
	Assistant Clinical Professor Division of Gynecologic Oncology SUNY-Health Science Center at Brooklyn	7/99-12/00
	Attending Physician Division of Gynecologic Oncology Kings County Hospital	7/99-12/00
<b>LICENSURE</b>	New York State- 201452	
<b>BOARD CERTIFICATION</b>	Obstetrics and Gynecology	11/2000-present
	Gynecologic Oncology	04/2002-present
<b>HOSPITAL APPOINTMENTS</b>	Kings County Hospital Attending Physician	7/99-12/00
	Downstate Medical Center Attending Physician	7/99-12/00
	Beth Israel Medical Center Attending Physician	1/01-02/06
	St. Luke's-Roosevelt Hospital Attending Physician	1/01-02/06
<b>ADMINISTRATIVE RESPONSIBILITIES</b>	Principal Investigator Gynecologic Oncology Group SUNY-Health Science Center at Brooklyn	7/99-
	Quality Assurance Committee Department of Obstetrics and Gynecology SUNY-Health Science Center at Brooklyn	7/99-12/00
	Blood Usage Committee Kings County Hospital	7/99-12/00
	Pain Management Committee SUNY-Health Science Center at Brooklyn	3/00-12/00
	Quality Assurance Committee	7/99-12/00

Kevin Holcomb, M.D.

Department of Obstetrics and Gynecology  
Kings County Hospital

Education Committee 1/01-3/06  
Department of Obstetrics and Gynecology  
Beth Israel Medical Center

Quality Assurance Committee 5/04- 3/06  
Department of Obstetrics and Gynecology  
Beth Israel Medical Center

Executive Council member 9/2004- 7/2005  
Metropolitan Gynecologic Cancer Society

Secretary 7/2005-7/2006  
Metropolitan Gynecologic Cancer Society

President 7/2007-7/2008  
Metropolitan Gynecologic Cancer Society

Chief Medical Officer 2005-2006  
American Cancer Society  
Upper Manhattan Office

President, Board of Advisors 2006- 2008  
American Cancer Society  
Upper Manhattan Office

Education Committee 2006- Present  
Department of Obstetrics and Gynecology  
NY-Presbyterian Hospital-Cornell

Quality Assurance Committee 2013- present  
Department of Obstetrics and Gynecology  
NY-Presbyterian Hospital-Cornell

Operations Committee 2013- present  
Department of Obstetrics and Gynecology  
NY Presbyterian Hospital-Cornell

Operating Room Committee 2013- present  
NY-Presbyterian Hospital-Cornell

Ambulatory Care Center 2013-present  
Planning Committee  
NY-Presbyterian Hospital-Cornell

Clinical Study Evaluation Committee 2013- present  
NY-Presbyterian Hospital-Cornell

Clinical Cancer Center Committee 2014-present

Associate Director, New York-Presbyterian 2010-2017  
Gynecologic Oncology Fellowship Program

Kevin Holcomb, M.D.

Co-Chair, Gynecologic Cancer Disease Management Team  
Meyer Cancer Center at Weill-Cornell Medicine 2017- present

New York City Department of Health Maternal Morbidity and Mortality Review Committee 2017-present

Meyer Cancer Center Executive Governance Committee 2017-present

Committee on Admissions Weill-Cornell Medical College 2018-present

**OTHER RESPONSIBILITIES**

Ad hoc reviewer *Gynecologic Oncology* 2003- Present  
Ad hoc reviewer *Am J Obstet Gynecol* 2010-Present  
Ad hoc reviewer *Clinical Cancer Research* 2003- 2004  
Ad hoc reviewer *JAMA* 2004- 2005  
Ad hoc reviewer *J of Clin Virology* 2015-present

**PROFESSIONAL ORGANIZATIONS**

ACOG, Fellow 12/01-present  
ABOG, Diplomat 11/2000-present  
New York Obstetrical Society 2004 -present  
Metropolitan Gynecologic Cancer Society 2005-2008  
Society of Gynecologic Oncologists 2002-present  
National Medical Association 1996-present

**CIVIC ORGANIZATIONS**

Kappa Alpha Psi Fraternity, Inc. 1985-present  
  
Sigma Pi Phi Fraternity 2004- present  
Westchester Boule  
  
Member, Harlem Cancer Control Coalition 2004- 2008

**HONORS AND AWARDS**

Metropolitan Life Foundation Award for Academic Excellence. 1989  
Alpha Omega Alpha, Iota Chapter. Inducted 1990  
Senior Award in Obstetrics and Gynecology. 1992  
CREOG National Faculty Teaching Award 2002  
CREOG National Faculty Teaching Award 2004  
The Network Journal "Best Black Doctors" 2005  
The Network Journal "40 Under 40" Achievement Award 2005  
Black Enterprise Magazine "The HotList; America's Most Powerful Players under 40" 2005

Kevin Holcomb, M.D.

Castle Connelly Medical Ltd., “Best Doctors in New York Metro Area”, 2009-2017  
New York Magazine “Best Doctors” 2010-2017  
Weill-Cornell Healthcare Leadership Fellows Program 2016

## PUBLICATIONS

Damario MA, Holcomb K, Bodack MP. Bilateral femoral neuropathy complicating a combined laparoscopic-vaginal procedure. *J Am Assoc Gynecol Laparosc*, 1996 Nov;4:1,69-72

Abulafia O, Sclafani S, Holcomb K, Gates EJ, Sherer D. Percutaneous transluminal endovascular graft placement for massive hemorrhage due to recurrent cervical cancer associated erosion of the external iliac artery. *Amer J Obstet Gynecol* . 1998 Mar; 178(3):618-620

Holcomb K, Maiman M, Dimaio T, Gates EJ. Rapid progression to invasive cervix cancer in a woman infected with the human immunodeficiency virus. *Obstet Gynecol* 1998 May; 91(5 pt. 2):848-850

Abulafia O, Cohen HL, Zinn DL, Holcomb K, Sherer D. Application of transvaginal ultrasound for the diagnosis of vesico-vaginal fistula. *J Ultrasound Med* 1998 (17); 333-335

Fruchter R, Maiman M, Arrastia CD, Matthews R, Gates EJ, Holcomb K. Is HIV Infection a Risk Factor for Advanced Cervical Cancer? *J Acquir Immune Defic Syndr Hum Retrovirol* 1998 Jul 1;18(3):241-245

Holcomb K, Abulafia O, Matthews RP, Gabbur N, Lee YC, Buhl A. The effect of pretreatment staging laparotomy on survival in locally advanced cervical carcinoma. *Eur J Gynecol Oncol* 1999;20(2):90-93

Holcomb K, Abulafia O, Montalto N, Lee YC, Matthews RP. Multiple solid tumors in a woman exposed to the excess radiation of the Chernobyl Nuclear Power Plant disaster. *Eur J Gynecol Oncol* 1999;20(3):174-176

Holcomb K, Matthews RP, Abulafia O, Chapman J, Lee YC, Buhl A. The significance of ASCUS in HIV-positive women. *Gynecol Oncol* 1999;75:118-121

Holcomb K, Matthews RP, Abulafia O, Chapman J, Lee YC, Buhl A. The efficacy of cervical conization in the treatment of cervical intraepithelial neoplasia in HIV-positive women. *Gynecol Oncol* 1999;74:428-431

Abulafia O, Ruiz J, Holcomb K, Dimaio T, Matthews R, Lee YC. Angiogenesis in Stage I invasive and low malignant potential epithelial ovarian carcinoma. *Obstet Gynecol* 2000 Apr 1;95(4):548-552.

Holcomb K, Francis M, Ruiz J, Abulafia O, Matthews R. Pleomorphic rhabdomyosarcoma of the uterus in a postmenopausal woman with elevated serum CA125. *Gynecol Oncol* 1999;74:499-501

Lee Y, Abulafia O, Montalto N, Holcomb K, Matthews R, Golub R. Malignant transformation of an ovarian mature cystic teratoma presenting as a rectal mass. *Gynecol Oncol* 1999;75(3):499-503

Lee YC, Min D, Holcomb K, Buhl A, DiMaio T, Abulafia O. Computed tomography guided core needle biopsy diagnosis of pelvic actinomycosis. *Gynecol Oncol* 2000; 79(2):318-323

Lee YC, Holcomb K, Buhl A, Holden J, Abulafia O. Rapid progression of primary vaginal squamous cell carcinoma in a young HIV infected woman. *Gynecol Oncol* 2000;78:380-382

Abulafia O, Matthews RP, Holcomb K, Buhl A, Lee YC. Magnetic resonance imaging in the preoperative determination of tumor resectability in previously irradiated groin tumor. *Gynecol Obstet Invest* 2001;51(2):143-4.

Kevin Holcomb, M.D.

Holcomb K, DiMaio TM, Nicastrì AD, Matthews RP, Lee YC, Buhl A. Cone biopsy and pathologic findings at radical hysterectomy in stage I cervical carcinoma. *Obstet Gynecol* 2001 Nov;98(5 Pt 1):779-82

Holcomb K, Gabbur N, Tucker T, Matthews R, Lee Y, Abulafia O. <sup>60</sup>Cobalt versus linear accelerator in the treatment of locally advanced cervix carcinoma: A comparison of survival and recurrence patterns. *Eur J Gynaecol Oncol*. 2001;22(1):16-9.

Buhl A, Landow S, Lee YC, Holcomb K, Heilman E, Abulafia O. Microcystic adnexal carcinoma of the vulva. *Gynecol Oncol* 2001 Sep;82(3):571-574

Holcomb K, Delatorre R, Pedemonte B, McLeod C, Anderson L, Chambers JT. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. *Obstet Gynecol* 2002 Dec;100(6):1290-95.

Holcomb K, Runowicz CD. Cancer Screening. Postgraduate Obstetrics and Gynecology. 2003 Mar;23(5):1-7

Seto-Young D, Leonardi O, Holcomb K, Park A, Salehi M, Chang P, Yih M, Rosenwaks Z, Poretsky L. Hormonally active non-transformed human ovarian cell culture from oophorectomy specimens: methods of development and characterization. *Horm Res*. 2005;64(5):238-47

Seto-Young D, Paliou M, Schlosser J, Avtanski D, Park A, Holcomb K, Chang P, Poretsky L. Thiazolidinedione action in the human ovary: direct effects on steroidogenesis and insulin-like growth factor binding protein-1 (IGFBP-1) production. *J Clin Endocrinol Metab*. 2005 Nov;90(11):6099-105

Seto-Young D, Avtanski D, Strizhevsky M, Parikh G, Patel P, Kaplun J, Holcomb K, Rosenwaks Z, Poretsky L. Interactions among peroxisome proliferator activated receptor-gamma, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells. *J Clin Endocrinol Metab* 92(6): 2232-9.

Dos Santos LA, Slomovitz BM, Huang M, Holcomb K, Ramirez PT, Caputo TA. Palliative laparoscopic end colostomy in a nonagenarian. *JSLS* 2008 Oct-Dec;12(4):410-13.

Huang M, Musa F, Holcomb K. Postoperative small bowel herniation through a 5mm non-bladed laparoscopic trocar site. *JSLS* 2010 Apr-Jun;14(2):289-91.

Huang M, Chadha MD, Musa F, Friedmann P, Kolev C, Holcomb K. Lymph nodes: is total number or station number a better predictor of lymph node metastasis in endometrial cancer? *Gynecol Oncol*. 2010 Nov;119(2):295-8

Adams BN, Brandt JS, Loukeris K, Holcomb K. Embryonal rhabdomyosarcoma of the cervix and appendiceal carcinoid tumor in a 43 year old woman. *Obstet Gynecol*. 2011 Feb;117(2 Pt 2):482-4.

Frey MK, Inhow SB, Heyman KP, Slomovitz BM, Kessler R, Worely MJ, Holcomb K. Minimally invasive staging of endometrial cancer is feasible and safe in elderly women. *J Minim Invasive Gynecol*. 2011 Mar-Apr;18(2):200-4.

Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. *Am J Obstet Gynecol*. 2011 Oct;205(4):358.e1-6.

Musa F, Huang M, Adams B, Pirog E, Holcomb K. Mucinous histology is a risk factor for nodal metastases in endometrial cancer. *Gynecol Oncol*. 2012 Jun;125(3):541-5.

Musa F, Frey MK, Im HB, Chekmereva M, Ellenson LH, Holcomb K. Does the presence of adenomyosis affect and lymph-vascular invasion affect the risk of lymph node metastases in patients with endometrioid adenocarcinoma of the endometrium? *Am J Obstet Gynecol*. 2012 Nov;207(5):417.e1-6.

Frey MK, Biewald M, Worely MJ, Taylor J, Lin SN, Holcomb K. Lynch syndrome awareness among medical students at a United States medical school. *Curr Womens Health Rev*. 2012 Aug;8(3):242-247.

Galic V, Schiavone MB, Herzog TJ, Holcomb K, Lewin SN, Lu YS, Neugut AI, Hershman DL, Wright JD. Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium. *Cancer Invest*. 2013 Aug;31(7):500-4.

Orfanelli T, Jeong J, Doulaveris G, Holcomb K, Witkin S. Involvement of Autophagy in Cervical, Endometrial and Ovarian Cancer. *Int J Cancer*. 2014 Aug 1;135(3):519-28

Nagar H, Boothe D, Parikh A, Yondorf M, Parashar B, Gupta D, Holcomb K, Caputo T, Chao KS, Nori D, Wernicke AG. Administration of concurrent vaginal brachytherapy during chemotherapy for treatment of endometrial cancer. *Int J Radiat Oncol Biol Phys*. 2013 Nov 15;87(4):665-9

Frey MK, Bashir S, Ward NM, Hensel KJ, Caputo TA, Holcomb KM, Baergen R, Gupta D. Role of surgical staging and adjuvant treatment in uterine serous carcinoma. *Eur. J. Gynaec. Oncol* 2013;24(5):453-456.

Kudesia R, Singer T, Caputo TA, Holcomb KM, Kligman I, Rosenwaks Z, Gupta D. Reproductive and oncologic outcomes after progestin therapy for atypical endometrial hyperplasia or carcinoma. *Am J Obstet Gynecol*. 2014 Mar;210(3):255.e1-4

Lin SN, Taylor J, Alperstien S, Hoda R, Holcomb K. Does speculum lubricant affect liquid-based Papanicolaou test adequacy? *Cancer Cytopathol*. 2014 Mar;122(3):221-6

Adams BN, Musa F, Taylor J, Holcomb K. AlloDerm graft mimicking uterine carcinosarcoma recurrence on PET/CT. *J Obstet Gynaecol* 2014 Jan;34(1):102-3.

Collins Y, Holcomb K, Chapman-Davis E, Khabele D, Farley JH. Gynecologic cancer disparities: A report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. *Gynecol Oncol*. 2014 May;133(2):353-61

Geynisman J, Pagan C, Pirog E, Holcomb K. Cotyledonoid dissecting leiomyoma. *Int J Gynaecol Obstet*. 2014 Jun;125(3):284

Frey MK, Taylor JS, Pauk SJ, Hughes D, Turbendian HK, Sapra KJ, Holcomb K. Knowledge of Lynch syndrome among obstetrician/gynecologists and general surgeons. *Int J Gynaecol Obstet*. 2014 Aug;126(2):161-4.

Bashir S, Jiang G, Joshi A, Miller C Jr., Matrai C, Yemelyanova A, Caputo TA, Holcomb KM, Ellenson LH, Gupta D. Molecular Alterations of PIK3CA in Uterine Carcinosarcoma, Clear Cell and Serous Tumors. *Int J Gynecol Cancer*. 2014 Sep;24(7):1262-7.

Taylor JS, Panico V, Caputo T, Gerber D, Gupta D, Pirog E, Holcomb K. Clinical outcomes of patients with adenocarcinoma in situ of the cervix treated by conization. *Eur J Gynaecol Oncol*. 2014;35(6):641-5.

Kevin Holcomb, M.D.

Frey MK, Lin JF, Stewart LE, Makaroun L, Panico VJ, Holcomb K. Comparison of two minimally invasive approaches to endometrial cancer staging: A single surgeon experience. *J Reprod Med*. 2015 Mar-Apr;60(3-4):127-34.

Lekovich JP, Amrane S, Pangasa M, Pereira N, Frey MK, Varrey A, Holcomb K. Comparison of Human Papillomavirus Infection and Cervical Cytology in Women Using Copper and Levonorgestrel-Containing Intrauterine Devices. *Obstet Gynecol* 2015;125(5):1101-1105

Tierney C, Dinkelspiel H, Bass A, Katzen J, Holcomb K. Sclerosing mesenteritis mimics gynecologic malignancy. *Gynecol Oncol Rep*. 2015 Mar 10;12:49-51

Cubillos-Ruiz JR, Silberman P, Rutkowski MR, Perales-Puchalt A, Song M, Bettigole S, Gupta D, Holcomb K, Ellenson LH, Caputo T, Lee AH, Conejo-Garcia AR, Glimcher L. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell lipid homeostasis. *Cell*. 2015 Jun 18;161(7):1527-38.

Orfanelli T, Doulaveris G, Holcomb K, Jeong J, Sisti G, Kanninen T, Caputo TA, Gupta D, Witkin S. Inhibition of autophagy in peripheral blood mononuclear cells by vaginal fluid from women with a malignant adnexal mass. *Int J Cancer*. 2015 Dec 15;137(12):2879-84.

Nasioudis D, Sisti G, Kanninen TT, Holcomb K, Di Tommaso M, Fambrini M, Witkin SS. Epidemiology and outcomes of squamous ovarian carcinoma; a population-based study. *Gynecol Oncol*. 2016 Apr;141(1):128-33.

Manzerova J, Sison CP, Gupta D, Holcomb K, Caputo TA, Parashar B, Nori D, Wernicke AG. Adjuvant radiation therapy in uterine carcinosarcoma: A population-based analysis of patient demographic and clinical characteristics, patterns of care and outcomes. *Gynecol Oncol*. 2016 May;141(2):225-30.

Chatterjee S, Gupta D, Caputo TA, Holcomb K. Disparities in Gynecological Malignancies. *Front Oncol*. 2016 Feb 22;6:36

Dinkelspiel HE, Matrai C, Pauk S, Pierre-Louis A, Chiu YL, Gupta D, Caputo T, Ellenson LH, Holcomb K. Does the Presence of Endometriosis Affect Prognosis of Ovarian Cancer? *Cancer Invest*. 2016 Mar 15;34(3):148-54.

Nagar H, Yan W, Parashar B, Nori D, Chao KS, Christos P, Gupta D, Holcomb K, Caputo T, Wernicke AG. Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma. *Am J Clin Oncol*. 2016 Mar 29

Nasioudis D, Sisti G, Holcomb K, Kanninen TT, Witkin SS. Malignant Brenner Tumors of the ovary; a population-based analysis. *Gynecol Oncol*. 2016 Jul;142(1):44-9

Fulmer CG, Hoda RS, Pirog EC, Park KJ, Holcomb K. Cytomorphology of Gastric-Type Cervical Adenocarcinoma on a ThinPrep Pap Test: Report of a p16-Positive Tumor Case. *Diagn Cytopathol*. 2016 May 11. doi: 10.1002/dc.23498

de Meritens AB, Kim J, Dinkelspiel H, Chapman-Davis E, Caputo T, Holcomb K. Feasibility and Learning Curve of Robotic Laparo-Endoscopic Single Site Surgery in Gynecology. *J Minim Invasive Gynecol*. 2016 Nov 17. pii: S1553-4650(16)31169-4.

Nasioudis D, Chapman-Davis E, Witkin SS, Holcomb K. Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma. *Gynecol Oncol*. 2016 Nov 28. pii: S0090-8258(16)31607-9

Nasioudis D, Alevizakos M, Holcomb K, Witkin SS. Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population. *Maturitas*. 2017 Feb;96:45-50.

Chaump M, Pirog EC, Panico VJ, D Meritens AB, Holcomb K, Hoda R. Detection of *in situ* and invasive endocervical adenocarcinoma on ThinPrep Pap Test: Morphologic analysis of false negative cases. *Cytojournal*. 2016 Dec 20;13:28.

Nasioudis D, Kampaktis PN, Frey M, Witkin SS, Holcomb K. Primary lymphoma of the female genital tract: An analysis of 697 cases. *Gynecol Oncol*. 2017 May;145(2):305-309

Nasioudis D, Kanninen TT, Holcomb K, Sisti G, Witkin SS. Prevalence of lymph node metastasis and prognostic significance of lymphadenectomy in apparent early-stage malignant ovarian sex cord-stromal tumors. *Gynecol Oncol*. 2017 May;145(2):243-247

Kanninen TT, Nasioudis D, Sisti G, Holcomb K, Di Tommaso M, Khalil S, Gojayev A, Witkin SS. Epidemiology of Second Primary Tumors in Women With Ovarian Cancer. *Int J Gynecol Cancer*. 2017 May;27(4):659-667

Nasioudis D, Chapman-Davis E, Frey M, Holcomb K. Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma. *J Gynecol Oncol*. 2017 Jul;28(4):e46

Nasioudis D, Alevizakos M, Chapman-Davis E, Witkin SS, Holcomb K. Rhabdomyosarcoma of the lower female genital tract: an analysis of 144 cases. *Arch Gynecol Obstet*. 2017 Aug;296(2):327-334

Nasioudis D, Chapman-Davis E, Frey MK, Caputo TA, Witkin SS, Holcomb K. Should epithelial ovarian carcinoma metastatic to the inguinal lymph nodes be assigned stage IVB? *Gynecol Oncol*. 2017 Oct;147(1):81-84

Nasioudis D, Chapman-Davis E, Frey MK, Caputo TA, Witkin SS, Holcomb K. Could fertility-sparing surgery be considered for women with early stage ovarian clear cell carcinoma? *J Gynecol Oncol*. 2017 Nov;28(6):e71

Nasioudis D, Chapman-Davis E, Frey MK, Caputo TA, Holcomb K. Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base. *Gynecol Oncol*. 2017 Nov;147(2):296-301

Nasioudis D, Frey MK, Chapman-Davis E, Witkin SS, Holcomb K. Safety of Fertility-Sparing Surgery for Premenopausal Women With Sex Cord-Stromal Tumors Confined to the Ovary. *Int J Gynecol Cancer*. 2017 Nov;27(9):1826-1832

Nasioudis D, Frey MK, Chapman-Davis E, Caputo TA, Holcomb K. Fertility-preserving surgery for advanced stage ovarian germ cell tumors. *Gynecol Oncol*. 2017 Dec;147(3):493-496

Nasioudis D, Chapman-Davis E, Frey MK, Caputo TA, Witkin SS, Holcomb K. Small Cell Carcinoma of the Ovary: A Rare Tumor With a Poor Prognosis. *Int J Gynecol Cancer*. 2018 Jun;28(5):932-938

Nasioudis D, Minis E, Chapman-Davis E, Frey MK, Caputo TA, Witkin SS, Holcomb K. Minimally Invasive Staging of Apparent Stage I Malignant Ovarian Germ Cell Tumors: Prevalence and Outcomes. *J Minim Invasive Gynecol*. 2018 Jun 9. pii: S1553-4650(18)30307-8

Song M, Sandoval TA, Chae CS, Chopra S, Tan C, Rutkowski MR, Raundhal M, Chaurio RA, Payne KK, Konrad C, Bettigole SE, Shin HR, Crowley MJP, Cerliani JP, Kossenkov AV, Motorykin I, Zhang S, Manfredi G, Zamarin D, Holcomb K, Rodriguez PC, Rabinovich GA, Conejo-Garcia JR, Glimcher LH,

Kevin Holcomb, M.D.

Cubillos-Ruiz JR. IRE1 $\alpha$ -XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. *Nature*. 2018 Oct;562(7727):423-428

Frey MK, Koppam RV, Ni Zhou Z, Fields JC, Buskwofie A, Carlson AD, Caputo T, Holcomb K, Chapman-Davis E. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center. *Cancer*. 2018 Nov 27. doi: 10.1002/cncr.31856. [Epub ahead of print].

Nasioudis D, Chapman-Davis E, Frey MK, Caputo TA, Witkin SS, **Holcomb K**. Prognostic significance of residual disease in advanced stage malignant ovarian germ cell tumors. *Int J Gynecol Cancer*. 2019 Jan 29. pii: ijgc-2018-000013. doi: 10.1136/ijgc-2018-000013. [Epub ahead of print]

# **EXHIBIT B**

**Testimony Given By**  
**Kevin Holcomb, M.D.**

***Ingham v. Johnson & Johnson***

Circuit Court of the City of St. Louis, State of Missouri

Case No. 1522-CC 10417-01

Deposition: May 7, 2018

Trial Testimony: July 9, 2018